Document:

Licenseing and Distribution Agreement dated May 11, 2007

 Exhibit 10.20 
 CONFIDENTIAL TREATMENT 
 LICENSING and DISTRIBUTION AGREEMENT 
 This AGREEMENT is entered into as of May 11, 2007 (herein referred to as EFFECTIVE DATE) by and between 
 Chemische Fabrik KREUSSLER & Co. GmbH with its registered office in 65203 Wiesbaden, Federal Republic of Germany, at Rheingaustrasse 87 - 93
(hereinafter referred to as KREUSSLER) 
 and 
 BioForm Medical, Inc. with its registered office in 1875 S. Grant Street, #110, San Mateo, CA 94402, USA (hereinafter referred to as LICENSEE) 
 Whereas, KREUSSLER is a company developing, manufacturing and marketing proprietary medicinal products; 
 Whereas, the
LICENSEE is marketing proprietary medicinal products and desires to market the PRODUCT(S) (as hereinafter defined) within the TERRITORY (as hereinafter defined) and KREUSSLER is willing to grant such right to the LICENSEE; 
 Whereas, the parties have exchanged certain information in the course of their respective due diligence investigation on this collaboration of which information only the
information contained in the Outline for Cooperation by KREUSSLER dated August 30, 2006 and the Memorandum by the LICENSEE dated September 5, 2006 shall be relevant for assessing the motivation and expectation of each party to enter into
this AGREEMENT; 
 Now, THEREFORE, the parties hereto agree as follows: 
 Article I – DEFINITIONS 
 Whenever used in this AGREEMENT, the following terms shall have the meaning
hereunder set forth: 
  

	 	a)	“AFFILIATE” of a party shall mean any person, corporation or other entity which, directly or indirectly through one or more intermediaries, controls, is controlled by, or
is under common control with such party, as the case may be. For the purposes of this AGREEMENT, “control” shall mean: 

 (i) to possess, directly or indirectly, the power to direct the management and policies of such person, corporation or other entity, whether through ownership of voting securities or by contract relating to voting rights or corporate
governance; or 
 (ii) direct or indirect beneficial ownership of at least fifty percent (50%) (or such lesser percentage which is the
maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital in such person, corporation, or other entity. 

	 	b)	“ASP” (or average selling price) means, with respect to any sales of each PRODUCT (UNIT) over any period of time, NET SALES during such period of time for the respective
PRODUCT (UNIT), divided by the number of UNITS of PRODUCTS sold (or shipped in connection with a sale as quantity discount) by the LICENSEE and its AFFILIATES during such period of time. SAMPLES shall not be considered in the calculation of the ASP,
such SAMPLES being invoiced according to Article VI d). 

  

	 	c)	“ASP PAYMENT” is herein defined as actual ASP multiplied by the applicable percentages, as defined in Annex II, used to determine transfer prices for UNITS of PRODUCT(S).

  

	 	d)	“COMPETITOR” of a party shall mean, in the case of a COMPETITOR of KREUSSLER, any company that manufactures, markets, promotes, sells and/or distributes COMPETING
PRODUCT(S) or is engaged (or its affiliate is engaged) in intellectual property-related litigation with KREUSSLER or its AFFILIATE reasonably judged to be material to this AGREEMENT and in the case of a COMPETITOR of LICENSEE, any company that
manufactures, markets, promotes, sells and/or distributes COMPETING PRODUCT(S) or is engaged (or its affiliate is engaged) in intellectual property-related litigation with the LICENSEE or its AFFILIATE reasonably judged to be material to this
AGREEMENT. 

  

	 	e)	“COMPETING PRODUCT” is herein defined as any technology or product other than saline (as long as saline is not marketed for sclerotherapy) that is or is likely to be used
as a sclerosing agent for the treatment of varicose veins manufactured by or for a third party. 

  

	 	f)	“COMPLAINT” is herein defined as any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability,
safety, effectiveness, or performance of a drug after it is released for distribution (marketed). 

  

	 	g)	“COMPLAINT EVALUATION” is herein defined as a documented process for determining the root cause (or the most probable cause) of a COMPLAINT. 

  

	 	h)	“CONFIDENTIAL INFORMATION” shall mean all information disclosed hereunder orally, visually, or through some other intangible media or in writing unless the disclosing
party expressly states that the disclosed information is of a non-confidential nature. Marketing material for use with third parties provided by KREUSSLER to the LICENSEE shall always be deemed to not constitute CONFIDENTIAL INFORMATION.

  

	 	i)	“EASI STUDY” shall mean the clinical trial initiated by KREUSSLER and ongoing as of the EFFECTIVE DATE intended for submission to the FDA for REGISTRATION in the
TERRITORY. 

  

	 	j)	“FDA” means the United States Food and Drug Administration, or any successor entity. 

  

 - 2 - 

	 	k)	“NET SALES” means the gross amount (excluding customary freight, shipping insurance and other transportation expenses) invoiced for PRODUCT(S) by the LICENSEE and its
AFFILIATES for the sale of PRODUCT(S) to any party other than the LICENSEE or an AFFILIATE, less the following amounts: 

 (i)
normal and customary trade, cash and quantity discounts actually given, rebates, credits, price adjustments or allowances for damaged products, returns or rejections of products; and 
 (ii) sales, value-added, excise taxes, tariffs and duties, and other taxes and government charges directly related to the sale or other disposition, to
the extent that such items are included in the gross invoice price and actually borne by the LICENSEE or its AFFILIATES without reimbursement from any third party. 
  

	 	l)	“POLIDOCANOL PRODUCT” is herein defined as any product containing polidocanol for the treatment of varicose veins (excluding esophageal varices) manufactured by or for
KREUSSLER and having obtained marketing authorization in any country. 

  

	 	m)	“PRODUCT(S)” shall mean the products listed in Annex I hereto which is hereby made an integral part of this AGREEMENT. The definition of PRODUCT(S) may be amended
from time to time to include additional POLIDOCANOL PRODUCT(S) in accordance with Article II (b). 

  

	 	n)	“QUARTER” shall mean the period of three (3) consecutive calendar months and ending on March 31, June 30, September 30 and December 31.

  

	 	o)	“REGISTRATION(S)” shall mean such licenses or authorizations required by the REGULATORY AUTHORITY of the TERRITORY for the manufacturing, importing, marketing,
distribution and selling of the PRODUCT(S). 

  

	 	p)	“REGULATORY AUTHORITY” shall mean the FDA, or a regulatory body with similar regulatory authority in any other jurisdiction. 

  

	 	q)	“SAMPLE” is herein defined as PRODUCT(S) labeled as “SAMPLE” and solely used for training purposes, in-office demonstrations, tradeshows and sent to employees of
the LICENSEE to be used in the promotion of the PRODUCT(S). 

  

	 	r)	“TERRITORY” shall mean the United States of America and its territories. The TERRITORY may be expanded to Canada and its territories in accordance with Article II (c).

  

	 	s)	“TRADEMARK(S)” shall mean the trademarks, trademarks applications, and proposed trademarks identified in Annex V and owned, filed, or proposed to be filed by
KREUSSLER in the TERRITORY, which list may be amended from time to time. 

  

 - 3 - 

	 	t)	“UNIT” shall mean one (1) box of PRODUCT containing 5 ampoules of 2 ml each or such other presentation/unit as defined in Annex I. 

 Article II – RIGHTS, OBLIGATIONS AND LIMITATIONS 
  

	 	a)	Subject to the terms and conditions of this AGREEMENT, KREUSSLER hereby grants to the LICENSEE 

 (i) the exclusive and nontransferable right to promote, have promoted, import, export with respect to Canada (provided the TERRITORY has been
expanded to Canada in accordance with Article II (c)), use, have used, distribute, have distributed, sell, offer for sale and have sold the PRODUCT(S) in the TERRITORY, and 
 (ii) the exclusive license to use the TRADEMARK(S) and NEW TRADEMARK(S) (as defined in Article IV (a)) with respect to the PRODUCT(S), but solely in
connection with its exercise of the above exclusive license. The LICENSEE shall have the right to sublicense the above exclusive license to its AFFILIATES and, subject to the prior written consent of KREUSSLER, which consent shall not be
unreasonably withheld, to any third party which shall agree in writing to be bound by the provisions of this AGREEMENT. 
  

	 	b)	From time to time, each party may elect to expand the scope of this AGREEMENT to include additional POLIDOCANOL PRODUCTS, to the extent that such products are not contained in the
definition of PRODUCT(S), along substantially similar terms as those in this AGREEMENT. The parties shall conduct good faith negotiations to amend this AGREEMENT accordingly, taking into account the costs and time associated with obtaining
REGISTRATION for such additional POLIDOCANOL PRODUCTS in the TERRITORY, the possible allocation of such costs and time between the parties, and expected transfer pricing. 

  

	 	c)	During the term of this AGREEMENT, the LICENSEE and its AFFILIATES shall have the exclusive option to enter into good faith negotiations with KREUSSLER to extend this AGREEMENT to
the territory of Canada. The term of the option shall be three (3) months from the date the LICENSEE or any of its AFFILIATES first notifies KREUSSLER of its decision to market the PRODUCT(S) in Canada. After expiration of the option term and
in the event the parties cannot agree on terms for amending this AGREEMENT to include Canada, KREUSSLER shall be free to offer the PRODUCT(S) for marketing in Canada to third parties. In the event that the LICENSEE or any of its AFFILIATES and
KREUSSLER agree to extend this AGREEMENT to the territory of Canada the term TERRITORY shall be amended accordingly. 

  

	 	d)	 During the term of this AGREEMENT, KREUSSLER agrees to sell PRODUCT(S) for use in the TERRITORY exclusively to the LICENSEE. KREUSSLER agrees to work in good faith
with LICENSEE to protect the LICENSEE’S exclusive rights in the TERRITORY. Neither KREUSSLER nor any of its AFFILIATES, shall promote, have promoted, sell or offer to sell, any POLIDOCANOL PRODUCTS inside the TERRITORY without the
LICENSEE’S prior written consent. 

  

 - 4 - 

	 	 
KREUSSLER further agrees to use its commercially reasonable efforts to prevent, to the extent legally permitted, the sale of any POLIDOCANOL PRODUCT for
resale or distribution within the TERRITORY by any party other than the LICENSEE or its AFFILIATES. Such prevention efforts could include amendment of existing third party contractor distribution agreements, and including provisions in future
distribution agreements to prevent and/or limit the sale of POLIDOCANOL PRODUCT(S) in the TERRITORY. 

 If any POLIDOCANOL
PRODUCT of KREUSSLER sold to third party contractor(s) of KREUSSLER is found to have been sold in the TERRITORY, KREUSSLER agrees to work with LICENSEE in good faith using commercially reasonable efforts, to prevent, to the extent legally permitted,
such sale in the TERRITORY. Such efforts could include the termination of sales to the third party contractor that breaches this exclusivity provision. KREUSSLER shall promptly notify the LICENSEE in the event it has reasonable suspicion to believe
that any POLIDOCANOL PRODUCT of KREUSSLER or provided or sold by KREUSSLER to any third party contractor has been sold in the TERRITORY and LICENSEE shall promptly notify KREUSSLER if it determines that any third party contractor has sold
POLIDOCANOL PRODUCTS in the TERRITORY. Parties agree that KREUSSLER and its AFFILIATES only have direct influence on their third party contractor(s), but not on “fourth party clients” (i.e. customers of KREUSSLER’S third party
contractor(s)); however KREUSSLER shall use good faith commercially reasonable efforts, to the extent legally permitted, to prevent sales to the TERRITORY by such “fourth party clients”. 
  

	 	e)	During the term of this AGREEMENT, neither the LICENSEE nor any AFFILIATE of the LICENSEE shall manufacture, have manufactured, promote, have promoted, sell or have sold
inside the TERRITORY any COMPETING PRODUCT(S) without KREUSSLER’s prior written consent. 

 If, during the term of
this AGREEMENT, the LICENSEE intends to introduce other technologies or products that may be applicable for use in the treatment of varicose veins (“OTHER PRODUCT”), the LICENSEE shall notify KREUSSLER of such intent and consult with
KREUSSLER on appropriate plans to provide proper continuing support for the commercialization of PRODUCT(S). LICENSEE will also provide, after such consultation, a written indication of the LICENSEE’S plans to maintain at least the same levels
of sales and marketing efforts for the PRODUCT(S) as before the introduction of the OTHER PRODUCT. 
 In the event that the LICENSEE
introduces OTHER PRODUCT inside the TERRITORY in accordance with the provisions of the second paragraph of this Article II (e), KREUSSLER shall have the right of first negotiation to enter into an exclusive licensing and distribution
agreement for such OTHER PRODUCT for any country outside the TERRITORY, provided that the LICENSEE shall only have this obligation if it has the right to enter into such an exclusive licensing and distribution agreement outside the TERRITORY
with respect to such OTHER PRODUCT. Upon notification of KREUSSLER’S intent to market such OTHER PRODUCT and the availability of the rights described above to the LICENSEE, the parties shall 

  

 - 5 - 

 
negotiate in good faith for a period of three (3) months to enter into an exclusive licensing and distribution agreement for such OTHER PRODUCT for such
country. After expiration of this option term, the LICENSEE shall be free to offer the OTHER PRODUCT to any third party for any such country outside the TERRITORY. 
 Article III – REGISTRATION OF THE PRODUCT(S), 
 REGULATORY AFFAIRS and PHARMACOVIGILANCE

  

	 	a)	KREUSSLER shall use commercially reasonable efforts to seek and obtain in its own name in the TERRITORY any necessary REGISTRATION, including marketing authorization, of the
PRODUCTS listed in Annex I as of the EFFECTIVE DATE, with the REGULATORY AUTHORITIES for the manufacture, use, distribution and sale of the such PRODUCTS in the TERRITORY for the indication of sclerotherapy of varicose veins (C1, spider veins
and reticular veins). 

 Unless the parties have agreed to an extension of the PRODUCT(S), listed in Annex I as of
the EFFECTIVE DATE to any new product(s) in accordance with the provisions of Article II (b) above, or to any indication other than the one referred to above, KREUSSLER shall not be obliged to seek and obtain any necessary REGISTRATION,
including marketing authorization, for such new product(s) or new indication. Unless the parties have agreed to an extension of the TERRITORY to Canada in accordance with the provisions of Article II (c) above, KREUSSLER shall not be obliged to
seek and obtain any necessary REGISTRATION, including marketing authorization, for the PRODUCT(S) in Canada. 
  

	 	b)	To the extent afforded by FDA regulations, and except as described below with respect to the EASI STUDY, the LICENSEE shall at its own expense maintain the REGISTRATIONS of the
PRODUCT(S) with the competent authorities for manufacture, use, distribution and sale of the PRODUCT(S) in the TERRITORY for and on behalf of KREUSSLER and KREUSSLER shall reasonably cooperate with LICENSEE as required for LICENSEE to fulfill this
obligation. If required by the FDA as a condition for approval, [****]. The LICENSEE shall obtain qualified regulatory personnel, or appoint at its own expense a qualified Regulatory Consultant, who, under the authorization of the LICENSEE, shall
promptly inform KREUSSLER in writing, by supplying the relevant documents, about all his services provided in relation to the PRODUCT(S). 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 6 - 

	 	c)	General Regulatory Affairs 

  

	 	i)	Information on issues related to drug regulatory affairs in the TERRITORY: The LICENSEE shall inform KREUSSLER, in writing and free of charge, about all material changes to
drug regulatory affairs (drug law, regulations, etc.) in the TERRITORY, to the extent that the LICENSEE becomes aware of such changes, that the LICENSEE believes will have a material impact on the PRODUCT(S). 

  

	 	ii)	Evaluation of the significance: Upon KREUSSLER’S request, a conference call among the parties may be arranged to discuss an assessment of the significance of the changes
described in Article III (c) (i) for the parties and the PRODUCT(S) and the performance of this AGREEMENT, which shall be summarized in writing by the LICENSEE, if requested by KREUSSLER. 

  

	 	d)	KREUSSLER clinical trials and REGISTRATION submission for the PRODUCT(S) pursuant to paragraph 1 of Article III (a): 

  

	 	i)	KREUSSLER agrees to complete the EASI STUDY in accordance with the timelines established on Annex VI. 

  

	 	ii)	Upon the completion of the EASI STUDY, KREUSSLER shall commit to taking all commercially reasonable steps required by the FDA, [****], otherwise sufficient to obtain REGISTRATION
for the PRODUCT(S) in the TERRITORY, including, without limitation, filing the appropriate clinical information with the FDA within [****] days after completion of the EASI STUDY (i.e. acceptance of the study report by KREUSSLER) to fulfill the
remaining requirements for the NDA (New Drug Application). 

  

	 	iii)	All regulatory filings in connection with the EASI STUDY shall be filed by KREUSSLER. Prior to submitting the documentation to the REGULATORY AUTHORITY, KREUSSLER will supply a copy
of all such applications and communications to the LICENSEE for review and consent, which consent shall not be unreasonably withheld or delayed. The LICENSEE shall communicate to KREUSSLER the result of its review together with any additional
comments within a reasonably short time after receipt of the respective application or communication documentation. KREUSSLER agrees to implement the LICENSEE’S material comments into the applications to or communication with the REGULATORY
AUTHORITY. 

  

	 	iv)	Should any competent authority including REGULATORY AUTHORITY in the TERRITORY request additional documentation except the conduct of a Post Marketing Registry study, which the
LICENSEE shall conduct pursuant to Article III (b) hereof, for 

  

	 	(a)	obtaining any REGISTRATION required to begin the marketing of either of the PRODUCT(S) listed in Annex II as of the EFFECTIVE DATE in the TERRITORY or 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 7 - 

	 	(b)	upholding and maintaining any REGISTRATION required for continuing the marketing either of the PRODUCT(S) listed in Annex II as of the EFFECTIVE DATE in the TERRITORY,

 the parties will enter into good faith discussions to address the requests for additional documentation and the estimated
necessary costs and time to fulfill these requirements and how to share these costs between the parties. If a mutually acceptable solution cannot be found within ninety (90) days, the parties agree to be governed by the NEW FDA REQUIREMENTS
RESOLUTION PROCESS. 
  

	 	v)	For the purposes of Article III (d) (iv) NEW FDA REQUIREMENTS RESOLUTION PROCESS shall be defined as the process to obtain a resolution to new requirements proposed by the
FDA. 

 KREUSSLER shall have a [****] option to initiate actions intended to fulfill the new requirements proposed by the FDA.

  

	 	(a)	If KREUSSLER proceeds with this option and assumes full responsibility in writing to fulfill the requirements, the terms of this AGREEMENT will remain unchanged. Once the additional
requirements are fulfilled and the parties receive an NDA for the PRODUCT(S), KREUSSLER shall provide the LICENSEE a written report summarizing the FULFILLMENT COSTS (as defined below). The LICENSEE will then reimburse [****] of the FULFILLMENT
COSTS in [****] installments following receipt of such NDA, the first installment becoming due [****] upon receipt of such NDA 

  

	 	(b)	If KREUSSLER does not proceed with this option, the LICENSEE shall have a [****] option to initiate actions intended to fulfill the new requirements proposed by the FDA. If the
LICENSEE elects to proceed with its option in writing, the LICENSEE shall have the right to fund and execute any and all actions, including without limitation any pre-clinical or clinical trials, additional data analyses and other activities, in
order to fulfill the requirements proposed by the FDA. All external costs associated with these activities (herein defined as “FULFILLMENT COSTS”), shall be the responsibility of the LICENSEE. Once the LICENSEE has obtained the necessary
information, KREUSSLER shall cooperate with the LICENSEE to submit the requirements to the FDA. 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 8 - 

 Once the additional requirements are fulfilled and the parties receive an NDA for the first PRODUCT(S),
the LICENSEE shall provide KREUSSLER a written report summarizing the FULFILLMENT COSTS. 
 The LICENSEE will then [****] to be made by the
LICENSEE to KREUSSLER by [****] for as long as the cumulative total of [****] to KREUSSLER are [****] the FULFILLMENT COSTS. Once the cumulative total of [****] is equal to [****] the FULFILLMENT COSTS, the LICENSEE shall cease to make [****] and
shall begin making [****] in accordance with the [****] as described in this AGREEMENT. 
  

	 	(c)	If neither KREUSSLER nor the LICENSEE proceed with their respective options in accordance with (a) and (b) above, the respective REGISTRATION required for continuing the
marketing of the PRODUCT(S) in the TERRITORY shall no longer be pursued, and each party may terminate this AGREEMENT with [****] written notice to the other party. 

  

	 	e)	Subject to the specific provisions in the foregoing paragraphs a) to d), the following sections e) to k) apply to all regulatory affairs. 

 Except as defined in Article III (d), the LICENSEE shall be solely responsible for all communications with and submission of applications and documents to
the REGULATORY AUTHORITY in the TERRITORY and costs associated with those communications and submissions. KREUSSLER shall permit the LICENSEE to use all relevant data owned by KREUSSLER necessary to support regulatory applications being made by the
LICENSEE in KREUSSLER’S name for PRODUCT(S) in the TERRITORY. It is understood that such applications shall only be made upon KREUSSLER’S prior written consent, which shall not be unreasonably withheld. KREUSSLER shall also permit the
LICENSEE to reference data owned by KREUSSLER in submissions to each REGULATORY AUTHORITY and permit the REGULATORY AUTHORITY to use such data in its reviews. The parties agree to cooperate on such activities along the following terms. 

 

	 	i)	Regulatory applications such as 

  

	 	(a)	applications for approval, maintenance and upholding of a marketing authorization for new POLIDOCANOL PRODUCT(S) as defined in Article II (b) and 

  

	 	(b)	variations, enhancements and revisions to the approved REGISTRATIONS for PRODUCT(S), 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 9 - 

 must be forwarded by the LICENSEE, in KREUSSLER’S name, to the REGULATORY AUTHORITY in the
TERRITORY. The LICENSEE shall complete these applications at its own cost unless the allocation of cost has been otherwise agreed between the parties, for example in an amendment to this AGREEMENT pursuant to Article II (b), according to the
authority’s directions, and, before submitting these applications to the REGULATORY AUTHORITY, forward a copy of these applications to KREUSSLER for review and consent, which consent shall not be unreasonably withheld or delayed. KREUSSLER
shall communicate to the LICENSEE the result of its review together with any additional comments within a reasonably short time after receipt of the respective documentation. The LICENSEE agrees to implement KREUSSLER’S material comments into
the applications to the REGULATORY AUTHORITY. 
 Subject to KREUSSLER’S written approval of an INDEPENDENT DEVELOPMENT-plan the LICENSEE
will have ability to conduct additional clinical trials at its own cost with the intent of extending the approved indications of PRODUCT(S) (“INDEPENDENT DEVELOPMENT”). KREUSSLER 
  

	 	(a)	shall cooperate with LICENSEE in an expeditious manner and as required by the REGULATORY AUTHORITY in the TERRITORY in order to permit LICENSEE to conduct such INDEPENDENT
DEVELOPMENT. Such cooperation shall include, but not be limited to, granting to LICENSEE and any LICENSEE designee access [****], solely to the extent necessary to support approval of any such pending or future INDs, REGISTRATIONs, applications or
submissions, and 

  

	 	(b)	shall transmit all necessary and appropriate letters to the FDA advising the FDA and other REGULATORY AUTHORITIES, as appropriate, that such body may rely upon filings on behalf of
LICENSEE or its designee in such circumstances, 

 and the LICENSEE shall reimburse KREUSSLER for all external costs associated
therewith. 
  

	 	ii)	To the extent not already supplied to the LICENSEE before signing of this AGREEMENT, and upon the LICENSEE’S periodic requests in connection with further regulatory filings as
agreed between the parties, KREUSSLER shall forward to the LICENSEE, free of charge, any necessary documentation for the PRODUCT(S) which is required by the LICENSEE for submission to the REGULATORY AUTHORITY. The LICENSEE shall review this
documentation immediately after receipt and inform KREUSSLER about the results of its review. If the documentation needs to be modified, the LICENSEE shall inform KREUSSLER thereof. The 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 10 - 

	 	 
modifications to be performed shall be detailed and explained in a brief statement by the LICENSEE. KREUSSLER shall promptly send the modified documentation
[****] to the LICENSEE for submission to the REGULATORY AUTHORITY. 

  

	 	iii)	Upon submission of the documentation to the REGULATORY AUTHORITY, the LICENSEE shall inform KREUSSLER about the date of submission, the expected duration of processing of the
application as well as the processing number and the progress of the application 

  

	 	iv)	The LICENSEE shall, promptly after generation of such data, provide KREUSSLER free of charge with copies of all data with respect to the PRODUCT(S) generated by or on behalf of the
LICENSEE, its AFFILIATES, or sub-licensees for the purpose of supporting any regulatory applications to and other communications with any REGULATORY AUTHORITY, including but not limited to clinical data, toxicity data, stability data, any other test
data, and any other information relating to any pending or future INDs, REGISTRATIONs, applications or submissions. KREUSSLER shall have the right to use such data and information for research and commercialization purposes, in particular to support
any regulatory applications by KREUSSLER for PRODUCT(S) outside of the TERRITORY. 

  

	 	v)	Each party shall promptly notify the other and provide to the other a copy or transcription, if available, of any decision, order or other communication from any REGULATORY
AUTHORITY relating to the PRODUCT(S), the marketing thereof, or any related matter (including copies of all REGISTRATIONS) and shall keep the other party reasonably apprised of regulatory interactions and similar activities with governmental
authorities and international bodies in connection with the PRODUCT(S) anywhere in the TERRITORY. 

  

	 	f)	All REGISTRATIONS shall be, or at the request of KREUSSLER become, the sole property of KREUSSLER. If in the future the parties agree that the LICENSEE shall become the formal
holder of the NDA, KREUSSLER shall receive a copy of each official decision, order or similar document; the originals shall be kept by the LICENSEE. 

  

	 	g)	Should the continued existence, the renewal or transfer of the REGISTRATION(S) depend on a declaration or action by the LICENSEE, the LICENSEE shall make this declaration or action
towards KREUSSLER or, as the case may be, the REGULATORY AUTHORITY on KREUSSLER’s request immediately and independently from any claim the LICENSEE might have against KREUSSLER. The LICENSEE waives any right of retention in this respect.

  

	 	h)	The LICENSEE shall take over from KREUSSLER all TERRITORY-related medical-scientific, medical marketing and pharmacovigilance responsibilities for the PRODUCT(S) and shall always
comply with any current laws and regulations 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 11 - 

	 	 
applicable in the TERRITORY. Details are set forth in Annex III of this AGREEMENT which shall be an integral part of the AGREEMENT. The LICENSEE shall
bear all costs in relation to the taking over of these responsibilities, including but not limited to the costs for any TERRITORY-related pharmacovigilance activities. 

  

	 	i)	The LICENSEE shall be responsible for all PRODUCT(S) related complaint handling activities, evaluations, analyses, and regulatory communications. The LICENSEE will enter all
COMPLAINTS, including related recommendations and analyses of KREUSSLER, into the LICENSEE’s complaint handling system. In connection with such COMPLAINT activities: 

  

	 	i)	At the LICENSEE’s request, KREUSSLER will cooperate and perform COMPLAINT evaluations for COMPLAINTS that may be the result of KREUSSLER’S actions (herein defined as
“PROCESS COMPLAINT”) in order to determine any required corrective actions. KREUSSLER will maintain records of such investigations as required by applicable cGMP. 

 Within the longer of (i) seven (7) calendar days following receipt of the PRODUCT(S) UNIT according to the following paragraph and
(ii) fifteen (15) calendar days from the time it receives a PROCESS COMPLAINT from the LICENSEE, KREUSSLER shall perform a preliminary investigation that evaluates the root cause of the COMPLAINT and makes a corrective action
recommendation. KREUSSLER will inform the LICENSEE immediately of the results of any such investigation and KREUSSLER’s recommendations. 
 Within a reasonable amount of time following a COMPLAINT, the LICENSEE will return to KREUSSLER or to such other agreed third party by express courier the PRODUCT(S) UNIT that is the subject of the COMPLAINT if such PRODUCT(S) has been made
available to the LICENSEE. 
 KREUSSLER will also maintain a cross reference system from KREUSSLER’s complaint handling system to the
LICENSEE’s complaint handling system. 
 KREUSSLER will take reasonable actions to complete all corrective actions in connection with a
PROCESS COMPLAINT within ninety (90) calendar days. The LICENSEE acknowledges that some corrective actions may take more than ninety (90) calendar days to complete. Upon the LICENSEE’s request, KREUSSLER will provide periodic updates
until all corrective actions are complete. KREUSSLER will provide the LICENSEE with a follow-up report on the effectiveness of the corrective actions within a reasonable time period. Without limiting the foregoing, to the extent required by
applicable law, the LICENSEE will report all COMPLAINT(S) to the relevant REGULATORY AUTHORITY in compliance with its obligations under Article III (j). 
  

 - 12 - 

	 	ii)	The LICENSEE will promptly notify KREUSSLER of any corrective actions generated by the LICENSEE relating to PRODUCT(S). Any such corrective actions that require action by KREUSSLER
will be specifically noted by the LICENSEE and KREUSSLER will provide a written response to the LICENSEE within fifteen (15) calendar days. The parties may agree to increase this time period. 

  

	 	j)	If, in the reasonable judgment of KREUSSLER or the LICENSEE, any PRODUCT(S) defect or any government action requires a recall of, or the issuance of an advisory letter regarding,
any PRODUCT(S), either party may undertake such recall or issue such advisory letter after consultation with the other party. Each party shall notify the other party in a timely manner prior to making any recall or issuing any advisory letter.

 The parties shall endeavor to reach an agreement prior to making any recall or issuing any advisory letter regarding the
manner, text, and timing of any publicity to be given such matters in time to comply with any applicable legal or regulatory requirements, but such agreement will not be a precondition to any action that either party deems necessary to protect users
of PRODUCT(S) or to comply with any applicable governmental orders, regulations, or mandates. The parties agree to provide reasonable assistance to one another in the event of any recall or issuance of any advisory letter. 
 The LICENSEE shall have the right to manage any recall within the TERRITORY so long as such management does not prevent KREUSSLER from exercising its
rights under this section. 
  

	 	k)	In the event of a recall of PRODUCT(S) attributable to KREUSSLER’S manufacture, packaging, testing, labeling, and storing or handling of PRODUCT(S), KREUSSLER shall correct
noted deficiencies (herein defined as “PROCESS RELATED RECALLS”), if applicable, or cause the vendor of any material, component, or sub-assembly incorporated into such PRODUCT(S) to do likewise with respect to such material, component, or
sub-assembly. 

 For PROCESS RELATED RECALLS, unless such PROCESS RELATED RECALLS result from a deficiency directly caused by
the LICENSEE, KREUSSLER shall, at KREUSSLER’S option, either, at its cost replace each UNIT of the PRODUCT(S) recalled (including UNITS held in inventory by the LICENSEE or its customers) if and in so far as such UNITS are affected by the
deficiency that was cause of the PROCESS RELATED RECALL with a corrected PRODUCT(S) within a reasonable period of time, or refund the purchase price. 
 KREUSSLER shall promptly pay or reimburse the LICENSEE for all documented and reasonable costs and expenses (including shipping, quality control testing, notification, and restocking costs) incurred by the LICENSEE as
a direct result of any PROCESS RELATED RECALLS or any advisory letter directly related to any PROCESS RELATED RECALLS or otherwise attributable to KREUSSLER’S manufacture, packaging, testing, labeling, and storing or handling of PRODUCT(S)

  

 - 13 - 

 
(unless resulting from a deficiency caused by the LICENSEE, in which case the LICENSEE will reimburse KREUSSLER for KREUSSLER’S documented and
reasonable costs and expenses associated with such recall or advisory letter). 
  

	 	l)	In the event of a recall of PRODUCT(S) attributable to any action or omission by the LICENSEE after delivery of the PRODUCT(S) to the LICENSEE, the LICENSEE shall correct noted
deficiencies (herein defined as “DISTRIBUTION RELATED RECALLS”), if applicable, or cause any third party involved in the storage, marketing, shipping or distribution of the PRODUCT(S) to do likewise with respect to such activity.

 For DISTRIBUTION RELATED RECALLS, KREUSSLER shall, at the request and at the cost of the LICENSEE, replace each UNIT of the
PRODUCT(S) recalled with a corrected PRODUCT(S) within a reasonable period of time. 
 The LICENSEE shall promptly pay or reimburse KREUSSLER
for all documented and reasonable costs and expenses (including shipping, quality control testing, notification, and restocking costs) incurred by KREUSSLER as a direct result of any DISTRIBUTION RELATED RECALLS or any advisory letter directly
related to any DISTRIBUTION RELATED RECALLS (unless resulting from a deficiency caused by KREUSSLER, in which case KREUSSLER will reimburse the LICENSEE for LICENSEE’S documented and reasonable costs and expenses associated with such recall or
advisory letter). 
 Article IV – TRADEMARK(S) 
  

	 	a)	The LICENSEE, in its sole commercial judgment, shall determine and notify KREUSSLER of the trademark to be used in connection with the marketing, the promotion and the sale of the
PRODUCT(S) in the TERRITORY, it being understood that the TRADEMARK(S) in Annex V would be the parties’ preferred trademark(s) for the PRODUCT(S). If the LICENSEE determines to use the TRADEMARK(S), the LICENSEE shall use the
TRADEMARK(S) in such manner as shall be advised and directed by KREUSSLER and solely for the purpose of fulfilling the LICENSEE’S obligations under this AGREEMENT. 

 If the trademark proposed by the LICENSEE is different from the TRADEMARK(S), the LICENSEE shall communicate its decision to KREUSSLER without delay to
obtain KREUSSLER’S consent to the LICENSEE’S use of such trademark (the “NEW TRADEMARK”), which consent shall not be unreasonably withheld. Subject to its consent, KREUSSLER shall make commercially reasonable efforts to obtain
such NEW TRADEMARK, and any of the TRADEMARK(S) not filed by KREUSSLER as of the EFFECTIVE DATE, in its own name in the TERRITORY. 
 In the
event, that the LICENSEE has obtained or will obtain a NEW TRADEMARK or any of the TRADEMARK(S) not filed by KREUSSLER as of the EFFECTIVE DATE, in its own name or the name of an AFFILIATE or a third party, the LICENSEE shall transfer or cause to be
transferred such NEW 

  

 - 14 - 

 
TRADEMARK or TRADEMARK to KREUSSLER without delay prior to its use for the PRODUCT(S) in connection with the marketing, promotion and sale in the TERRITORY.

  

	 	b)	During the term of this AGREEMENT, KREUSSLER and its AFFILIATES will not use the NEW TRADEMARK(S) inside the TERRITORY for the benefit of any party other than the LICENSEE, without
the LICENSEE’S written consent, which shall not be unreasonably withheld. 

  

	 	c)	KREUSSLER’S company name/logo will be named on the PRODUCT(S) in compliance with applicable regulatory requirements (e.g. card box). 

  

	 	d)	The LICENSEE acknowledges KREUSSLER’S ownership of and/or right to the TRADEMARK(S) and NEW TRADEMARK(S) and shall not at any time do or cause to be done or suffer to be done
any act or thing which might in any way impair the right thereto of KREUSSLER or the validity of the TRADEMARK(S) and NEW TRADEMARK(S). 

  

	 	e)	The LICENSEE shall not acquire nor cause to be acquired and shall not claim nor cause to be claimed any right to the TRADEMARK(S) and NEW TRADEMARK(S) by virtue of the rights herein
granted or through the LICENSEE’S use of the TRADEMARK(S) and NEW TRADEMARK(S). 

  

	 	f)	The LICENSEE shall not during the term hereof or upon expiration or termination hereof for any reason whatsoever, register nor cause to be registered or use or cause to be used any
trademarks which are the same as, or confusingly similar to, the TRADEMARK(S) and NEW TRADEMARK(S) themselves or in combination with any other words, symbols, signs or designs. The LICENSEE further agrees that it will not use or cause or allow the
TRADEMARK(S) or NEW TRADEMARK(S) to be used, directly or indirectly, as part of any corporate or firm name or for any other purpose than herein permitted. 

  

	 	g)	The LICENSEE is authorized to use the TRADEMARK(S) and NEW TRADEMARK(S) in the TERRITORY according to local applicable law or requirements and in accordance with the provisions of
this AGREEMENT. The LICENSEE shall co-operate in effecting any such recording. The cost of the aforestipulated recording or its renewals shall be the responsibility of KREUSSLER. 

  

	 	h)	KREUSSLER undertakes to maintain all of the TRADEMARK(S) already registered in the name of KREUSSLER or filed by KREUSSLER as of the EFFECTIVE DATE in the TERRITORY and not used by
the LICENSEE for the maximum period possible under the applicable laws. KREUSSLER undertakes to maintain all of the TRADEMARK(S) and NEW TRADEMARK(S) used by the LICENSEE in connection with the PRODUCT(S) during the term of this AGREEMENT at its own
cost and agrees to diligently and promptly exert its reasonable efforts to protect its interests and the TRADEMARK and NEW TRADEMARK from acts of infringement in the TERRITORY. 

  

 - 15 - 

	 	i)	The LICENSEE shall immediately notify KREUSSLER upon obtaining the knowledge of the use by any other person, firm or corporation of the TRADEMARK(S) or NEW TRADEMARK(S) or trade
names confusingly similar thereto which might constitute an infringement of KREUSSLER’s right to the TRADEMARK(S) and NEW TRADEMARK(S). 

  

	 	j)	Immediately upon expiration or termination of the AGREEMENT for any reason whatsoever, the LICENSEE shall discontinue the use of the TRADEMARK(S) and NEW TRADEMARK(S) in any manner
whatsoever and/or on any documentation, material, display and/or stationary whatsoever which may make it appear that the LICENSEE is still selling the PRODUCT(S) by authority of KREUSSLER or being the agent or representative KREUSSLER in any way
whatsoever. 

  

	 	k)	For the avoidance of doubt, in any case, upon expiration or termination of this AGREEMENT for any reason whatsoever, KREUSSLER or its assignees or successors, as their respective
interest may appear, shall remain the sole owner(s) of all TRADEMARK(S) and NEW TRADEMARK(S). 

  

	 	l)	Notwithstanding anything to the contrary herein contained, the provisions of the foregoing Article IV (j) and Article IV (k) shall survive expiration and termination
hereof for any reason whatsoever. 

 Article V – MARKETING, DISTRIBUTION 
  

	 	a)	The LICENSEE shall market, at its own expense, each PRODUCT in the TERRITORY within [****] upon receipt of all corresponding REGISTRATIONS necessary for commercialization.

  

	 	b)	The LICENSEE shall use commercially reasonable efforts to continuously increase the sale of the PRODUCT(S) in the TERRITORY during the term of this AGREEMENT so long as KREUSSLER
supplies PRODUCT(S) to the LICENSEE in accordance with the terms of this AGREEMENT. Provided that 

  

	 	i)	the LICENSEE shall not be required to use any level of efforts to sell, market, or distribute the PRODUCT(S) in the TERRITORY prior to receipt of all REGISTRATIONS reasonably deemed
by the LICENSEE to be necessary for the marketing and sale of the PRODUCT(S) in the TERRITORY; and 

  

	 	ii)	whether certain efforts by the LICENSEE are deemed to be “commercially reasonable” with respect to the PRODUCT(S) shall be determined in light of all relevant factors in
the relevant TERRITORY including, but not limited to: 

  

	 	(a)	the LICENSEE’S reasonable estimate of the market potential and rate of market growth of the PRODUCT(S) (including anticipated profit margin and the perceived market size);

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 16 - 

	 	(b)	the level of REGISTRATION for the PRODUCT(S) in the TERRITORY (including the extent of the indications, if any, within the TERRITORY); 

  

	 	(c)	in the LICENSEE’S reasonable estimation, whether or not the sale of the PRODUCT(S) infringes or could infringe the patent rights of third persons in the TERRITORY;

  

	 	(d)	the competitive position of the PRODUCT(S) vis-à-vis other products that may be marketed and sold for the treatment of the same indications, including with respect to the
safety, efficacy, and cost of the PRODUCT(S) when compared to such other products; and 

  

	 	(e)	the availability and supply of the PRODUCT(S) for distribution. 

  

	 	c)	Upon KREUSSLER’S request, and in six (6) calendar month intervals, beginning with the receipt of all necessary REGISTRATIONS, the LICENSEE shall submit to KREUSSLER a
half-year report on the marketing of each PRODUCT including, competition, regulatory trends, and pricing trends. 

  

	 	d)	Upon KREUSSLER’S request and beginning with the marketing of each PRODUCT, the LICENSEE shall report, in electronic format, the sales figures for each PRODUCT in quantity and
value and, to the extent available, any price change (ex factory, per batch, prices to different customer-groups and, if applicable, price of reimbursement) within the forty five (45) days after the end of each QUARTER.

  

	 	e)	The LICENSEE shall promote the PRODUCT(S) in accordance with all laws and regulations of the TERRITORY and in conformity with KREUSSLER’s guidance as to the use (indications,
contraindications etc.) of the PRODUCT(S). Subject to all applicable laws in the TERRITORY, the LICENSEE will retain the rights to produce all clinical education, physician and patient marketing materials the LICENSEE deems to be necessary and
advisable for the commercialization of the PRODUCT(S) in the TERRITORY. In order to ascertain the compliance with KREUSSLER’s global marketing policy for the PRODUCT(S), the parties will work together to create a marketing claims overview
document, which outlines, subject to applicable laws and regulations, the claims that the LICENSEE will be allowed to make with respect to the marketing of the PRODUCT(S). 

  

	 	f)	Without prejudice to the LICENSEE’s obligation to verify that promotion of the PRODUCT(S) is in accordance with all laws and regulations of the TERRITORY, KREUSSLER, upon the
LICENSEE’S request, shall provide to the LICENSEE scientific and medical data and brochures related to the PRODUCT(S). Such materials will be made available to the LICENSEE at KREUSSLER’s cost to manufacture such materials.

  

	 	g)	 KREUSSLER shall during the term hereof also inform, from time to time, the LICENSEE of its newest medical-scientific data with respect to the PRODUCT(S).
Furthermore, KREUSSLER shall, from time to time, contact the LICENSEE orally or in writing to inform them of KREUSSLER’S experiences in the marketing and 

  

 - 17 - 

	 	 
selling of the PRODUCT(S) and assist the LICENSEE in the instructions of the medical representatives/sales force by submitting relevant documentation, it
being understood that such instruction of the medical representatives shall be based on the documentation handed over in connection with the REGISTRATION. 

  

	 	h)	The LICENSEE shall store and distribute the PRODUCT(S) in accordance with all applicable laws and regulations of the TERRITORY, including applicable warehousing and distribution
procedures set forth in 21 CFR Part 211, Subpart H, and, in addition, in conformity with standard industry practices. 

 KREUSSLER shall have the right to have its representatives present at the plant or plants at which PRODUCT(S) are stored and shipped and other activities under this AGREEMENT are performed during normal business hours to conduct an initial
and periodic inspections of such facilities and storage, marketing, shipping, distribution and pharmacovigilance procedures for compliance with applicable laws, regulations and standards including those set forth in Article III (h) and Article
V (e) and (h), and to inspect the LICENSEE’S inventory of PRODUCT(S), order/shipping records, quality manuals, regulatory dossiers, and such other matters as may be pertinent to ensure proper quality assurance of PRODUCT(S) to be stored,
marketed, shipped and distributed hereunder; 
 it being understood that the parties do not expect more than one (1) inspection (up to
two (2) days) every second year, unless required by the LICENSEE’S or its AFFILIATE’S compliance status. 
 KREUSSLER agrees to
give the LICENSEE a minimum of twenty (20) business days prior notice of any such inspection. The LICENSEE shall promptly use its best efforts to take such action as is required to correct any deficiencies identified by KREUSSLER and accepted
by the LICENSEE relating to LICENSEE’S obligations concerning the PRODUCT(S). The LICENSEE further agrees to use its best efforts to provide such documentation or conduct such measures as KREUSSLER may reasonably request in connection with any
regulatory submission or audit. At KREUSSLER’S reasonable request, the LICENSEE will perform a quality system assessment of the AFFILIATE(s), Sub-Licensee(s) or other contractor(s) involved in connection with the storage, marketing, shipment
and distribution of the PRODUCT(S) and the LICENSEE shall promptly notify the KREUSSLER of the results of such assessments. 
  

 - 18 - 

 Article VI – PRICES 
  

	 	a)	SUPPLY PRICES 

  

	 	i)	The supply prices for the PRODUCT(S) are stipulated in Annex II which is hereby made an integral part of this AGREEMENT. 

  

	 	ii)	The PRODUCT(S) shall be invoiced in USD to the LICENSEE according to the payment terms as stipulated in Article VI (b) and Annex II and as indicated on the invoice.
However, KREUSSLER reserves the right to change method of payment into payment in advance if [****] do not reach KREUSSLER in accordance with the payment terms in Annex II. 

  

	 	iii)	Following Year 8, the parties agree to use commercially reasonable, good faith efforts to negotiate adjustments to the minimum price if 

  

	 	(a)	requested by KREUSSLER, and only if KREUSSLER’S cost to manufacture PRODUCT(S) [****] since the EFFECTIVE DATE or [****] since the latest prior price adjustment; or

  

	 	(b)	requested by the LICENSEE, upon the occurrence of a change in market dynamics that results in the LICENSEE [****] since the EFFECTIVE DATE or [****] since the latest prior price
adjustment. 

  

	 	b)	PAYMENT 

  

	 	i)	The invoice pursuant to Article VI (a) (ii) shall be calculated on the basis of the minimum transfer price for each PRODUCT. If the LICENSEE is in dispute of a specific
invoice, LICENSEE shall be entitled to withhold the disputed amount of such invoice until resolution of such dispute. 

  

	 	ii)	Within forty five (45) days following the end of every QUARTER, the LICENSEE shall calculate the actual ASP PAYMENT due for the PRODUCT(S) that have been sold in that QUARTER
and shall provide KREUSSLER with a report showing 

  

	 	(a)	gross sales of each PRODUCT(S) and quantity of UNIT(S) sold of such PRODUCT(S) in the TERRITORY for that QUARTER; 

  

	 	(b)	a calculation demonstrating the adjustments to gross sales in order to arrive at the NET SALES and ASP; and 

  

	 	(c)	the calculation of the ASP PAYMENT. 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 19 - 

	 	iii)	If the ASP PAYMENT due for the PRODUCT(S) UNIT(S) sold in that QUARTER is lower than the minimum transfer prices paid for such UNIT(S), no further supply price payment will be due
for that QUARTER. 

 If the ASP PAYMENT due of the PRODUCT(S) UNIT(S) sold in that QUARTER is greater than the minimum transfer
prices paid for such UNIT(S), then the LICENSEE shall pay the difference between the ASP PAYMENT and the actual minimum transfer prices paid for such UNIT(S). This reconciliation payment shall be made to KREUSSLER 45 (forty five) days following the
end of the QUARTER for which the reconciliation payment shall be made. 
  

	 	iv)	If KREUSSLER, in its reasonable judgement, determines that an audit of the LICENSEE’S relevant books and records is necessary to verify the information supplied by the LICENSEE
pursuant to Article VI (b) (ii) and Article VIII (a) (vii), then KREUSSLER or, upon the LICENSEE’s request KREUSSLER’s designee, under duty of confidentiality to KREUSSLER and the LICENSEE, and provided such designee is an
independent certified public accountant, shall have the right, on twenty (20) days advance written notice, at KREUSSLER’S expense, to perform an audit of the relevant books and records of the LICENSEE not more than once in any twelve
(12) month period to verify the information supplied by the LICENSEE. The designee shall report only the amounts which the designee believes to be due and payable hereunder. If an audit reveals that there has been a variance of 2% or more in
the determination of the applicable ASP or, as the case may be, NET SALES, then the cost for such audit shall be paid by the LICENSEE. 

  

	 	c)	LOCAL PRICES 

  

	 	i)	Nothing contained herein shall be deemed to limit in any way the right of the LICENSEE to determine the prices at which, or the terms on which, PRODUCT(S) purchased by the LICENSEE
may be resold by the LICENSEE. 

  

	 	d)	LAUNCH AND TRAINING. 

  

	 	i)	Upon KREUSSLER’S request, the LICENSEE will certify in writing that the SAMPLE PRODUCT UNIT(S) provided to the LICENSEE under this section were used in accordance with the
definition of SAMPLE(S) and that they were not sold to third parties. In the event of a YEAR 0, the first [****] SAMPLE(S) for YEAR 0 shall be invoiced at [****] of the minimum transfer price per UNIT. Thereafter all SAMPLES shall be invoiced at the
minimum transfer price, as defined in Annex II, for the given year. 

  

	 	ii)	For YEAR 1, the [****] SAMPLE(S) shall be invoiced at [****] of the minimum transfer price per UNIT. Thereafter all SAMPLES shall be invoiced at the minimum transfer price, as
defined in Annex II, for the given year. 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 20 - 

	 	iii)	For YEAR 2, the [****] SAMPLE(S) shall be invoiced at [****] of the minimum transfer price per UNIT. Thereafter all SAMPLES shall be invoiced at the minimum transfer price, as
defined in Annex II, for the given year. 

  

	 	iv)	Following the end of YEAR 2, all SAMPLES shall be invoiced at the minimum transfer price, as defined in Annex II, for the given year. 

 Article VII – MANUFACTURING and SUPPLY 
  

	 	a)	The LICENSEE shall purchase the PRODUCT(S) exclusively from KREUSSLER. 

  

	 	b)	By the end of every month following the REGISTRATION of the PRODUCT(S) in the TERRITORY, the LICENSEE will specify its demand for the coming twelve (12) months of each PRODUCT
by mentioning quantities and desired delivery dates for the PRODUCT (“ROLLING FORECAST”). 

  

	 	c)	With each ROLLING FORECAST submitted to KREUSSLER, the LICENSEE shall submit monthly binding purchase orders to cover one hundred percent (100%) of the PRODUCT UNIT(S) included
in such ROLLING FORECAST for the seventh month, the delivery period not being less than six (6) months from the date of the binding purchase order, unless otherwise agreed by KREUSSLER (Example: By the end of the month “zero” on
December 31 the LICENSEE must place a binding order for the month July). With each ROLLING FORECAST, LICENSEE, at its discretion, may also place binding purchase orders for periods after the seventh month of the ROLLING FORECAST and the
delivery period for those orders will be as specified by LICENSEE in the purchase order (so long as the delivery period is not less than six (6) months from the date of the purchase order unless otherwise agreed to by KREUSSLER). PRODUCT
UNIT(S) forecast for the periods of the eight to twelfth month of the ROLLING FORECAST, for which no binding purchase order has been submitted according to the previous sentence, shall be non-binding. 

  

	 	d)	Each binding purchase order may (once per purchase order) be increased by the LICENSEE by up to [****] prior written notice. 

 KREUSSLER shall not be obligated to supply any such excess above the [****], however, KREUSSLER shall use its commercially reasonable efforts to supply
such excess. 
  

	 	e)	With the same purchase order according to Article VII (c), the LICENSEE shall confirm the exact delivery dates for this period mentioned in the ROLLING FORECAST and duly correct
them, if necessary. The order becomes binding for KREUSSLER when accepted in writing. KREUSSLER shall only be obliged to supply PRODUCT(S) to the LICENSEE if full payment for all prior quantities of PRODUCT(S) supplied from KREUSSLER to the LICENSEE
has been received by KREUSSLER in accordance with this AGREEMENT. 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 21 - 

 In each calendar year during the term of this AGREEMENT following Year 3, KREUSSLER shall not be obliged
to produce more than [****] of the quantity of the total PRODUCT(S) produced by KREUSSLER in the preceding calendar year, provided, however, KREUSSLER will use best faith efforts to meet such increased demand. 
  

	 	f)	For the purposes of this AGREEMENT “Years” are defined as calendar years following commercial launch of the PRODUCT(S). Should the commercial launch of a PRODUCT take
place on or after July 1 of a calendar year, for reasons of practicability the remaining part of such calendar year shall be regarded as “Year 0”; until December 31 of this “Year 0”, the minimum annual purchase
obligation shall be the pro rata temporis-amount calculated on the basis of the minimum annual purchase obligation from Year 1 as set forth in Annex II. Should the launch of a PRODUCT take place before July 1 of a calendar year, such calendar
year shall be regarded as “Year 1” and the minimum annual purchase obligations for this Year 1 as set forth in Annex II shall remain unchanged. 

  

	 	g)	The LICENSEE guarantees to purchase the minimum UNITS of the PRODUCT(S) in each Year as defined in Annex II. 

  

	 	h)	If the parties agree to a change in packaging of the PRODUCT(S) that effects the quantity of PRODUCT in a UNIT as of the EFFECTIVE DATE, the parties will agree on a mechanism to
proportionally amend the minimum annual purchase amount defined in Annex II. 

  

	 	i)	KREUSSLER shall agree to the minimum UNITS for each Year after Year 4 with the LICENSEE. The calculation after Year 4 shall be made ninety (90) days prior to the beginning of
each consecutive Year and shall take into account the sales during the current and previous calendar year. If no agreement is reached as to the minimum quantity target within that ninety (90) day period, the LICENSEE shall increase the previous
minimum annual purchase amount by [****] for each consecutive Year. 

 If the minimum annual purchase amount in a calendar year
for a PRODUCT is not met, KREUSSLER may at its discretion either (i) terminate the AGREEMENT for the respective PRODUCT by giving not less than [****] months written notice, unless LICENSEE has cured, or has initiated steps to cure, such breach
within [****] months after the end of the previous calendar year, or (ii) ask the LICENSEE to pay to KREUSSLER within thirty (30) days after the end of each calendar year the difference between the purchase price of the quantities of
PRODUCT actually purchased by the LICENSEE from KREUSSLER in the preceding calendar year and the aggregated purchase price for the quantities of PRODUCT calculated on the basis of the minimum annual purchase volume for such calendar year.

  

	 	j)	The LICENSEE shall permanently keep a stock of an approximate [****] months supply of PRODUCT(S). 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 22 - 

	 	k)	KREUSSLER shall permanently keep a stock of an approximate [****] months supply of PRODUCT(S), of which up to [****] may be stored as semi-finished product (naked ampoules).

 KREUSSLER shall use commercially reasonable efforts to maintain a minimum stock of [****] sufficient to produce [****] months
of PRODUCT(S), calculated as [****] the latest ROLLING FORECAST. 
  

	 	l)	KREUSSLER will ensure the manufacture of the PRODUCT(S) in accordance with the then-current 

  

	 	i)	products specifications agreed to by the FDA as contained in Annex IV (the “PRODUCT SPECIFICATIONS”), 

  

	 	ii)	applicable regulations relating to current Good Manufacturing Practices (“cGMP”), quality system regulations of the FDA (“QSR”), including but not limited to
master batch records, and 

  

	 	iii)	other pertinent rules and regulations of the REGULATORY AUTHORITY that has approved the sale of the PRODUCT(S) in the TERRITORY (in such case (iii) the LICENSEE will inform
KREUSSLER in time of such rules and regulations). 

 KREUSSLER shall include written evidence of compliance with the criteria
set forth in the preceding sentence (Certificate of Analysis) in each order delivered to the LICENSEE. 
 During the term of this AGREEMENT,
KREUSSLER will maintain, or cause to be maintained at its contract manufacturer(s), the PRODUCT(S) manufacturing facility’s registration as a certified drug manufacturing facility with all applicable REGULATORY AUTHORITIES or cause such
facility to be maintained such that the facility would pass an audit for compliance with cGMP and QSR. KREUSSLER shall maintain ongoing quality assurance and testing policies sufficient to satisfy its obligations under this AGREEMENT, the
LICENSEE’s standard requirements for approval as a vendor as described in the LICENSEE’s quality system review policy, and KREUSSLER’s standard quality assurance policies. For one year beyond the shelf life of each PRODUCT(S) UNIT
delivered to the LICENSEE, or such longer period as may be required by cGMP and other applicable rules and regulations of any REGULATORY AUTHORITY in the TERRITORY upon prior information by the LICENSEE, KREUSSLER shall maintain traceability for
each lot of PRODUCT(S) UNIT including the manufacturing date and lot number of each PRODUCT(S) UNIT and each component and material comprising each PRODUCT(S) UNIT and provide the LICENSEE a copy of such records upon the LICENSEE’s written
request. 
  

	 	m)	The LICENSEE shall have the right to have its representatives present at the plant or plants at which PRODUCT(S) are manufactured during normal business hours to conduct an initial
and periodic inspections of such facilities and manufacturing procedures for compliance with cGMP and QSR, the PRODUCT 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 23 - 

	 	 
SPECIFICATIONS and to inspect KREUSSLER’S inventory of PRODUCT(S), work-in-process, raw materials to be used for PRODUCT(S), production records, design
history file, quality manuals, regulatory dossiers, and such other matters as may be pertinent to ensure proper quality assurance of PRODUCT(S) to be delivered hereunder; 

 it being understood that the parties do not expect more than one inspection (up to 2 days) every second year, unless required by KREUSSLER’S or its
AFFILIATE’S compliance status. 
 The LICENSEE agrees to give KREUSSLER a minimum of twenty (20) business days’ prior notice of
any such inspection. KREUSSLER shall promptly use its best efforts to take such action as is required to correct any deficiencies identified by the LICENSEE and accepted by KREUSSLER relating to the production of PRODUCT(S). KREUSSLER further agrees
to use its best efforts to provide such documentation or conduct such analyses as the LICENSEE may reasonably request in connection with any regulatory submission or audit. At the LICENSEE’S reasonable request, KREUSSLER will perform a quality
system assessment of the vendors who provide KREUSSLER with raw components/materials, sub-assemblies or contract services in connection with the PRODUCT(S) and KREUSSLER shall promptly notify the LICENSEE of the results of such assessments.

  

	 	n)	Without prejudice to the provisions set forth in Annex III, each party shall notify the other as soon as possible, but in no case later than fifteen (15) calendar days
by fax, with confirming notice via overnight delivery, as soon as it becomes aware of any critical or severe quality issue with PRODUCT(S) or their testing, manufacture, labeling, or packaging, occurring within the TERRITORY or, in so far as the
PRODUCT(S) in the TERRITORY might be affected, outside of the TERRITORY, including any critical or severe quality issue relating to regulatory compliance, safety or efficacy of PRODUCT(S) . A quality issue shall be deemed to be “critical”
or “severe” if it could reasonably be expected to affect the PRODUCT(S), in a way that it may potentially cause 

  

	 	i)	either severe health damage, such as: wrong product (declaration and content do not correspond, microbial contamination of sterile injectable product(s), chemical contamination with
severe medical consequences, mix-ups of other products to significant extent, or 

  

	 	ii)	illness or mistreatment, such as false or missing product information, false or missing texts, insufficient closure with severe medical consequences. 

 Without limiting the generality of the foregoing, each party will notify the other as soon as possible, but in no case later than fifteen
(15) calendar days if it becomes aware of any regulatory inspections or other communications with REGULATORY AUTHORITIES related to the PRODUCT(S) that would materially impact the PRODUCT(S) or the party’s performance of its
responsibilities hereunder. 
  

	 	o)	 All PRODUCT(S) delivered by KREUSSLER hereunder shall be in full compliance with PRODUCT SPECIFICATIONS as described in Annex IV, shall have a 

  

 - 24 - 

	 	 
minimum of [****] year shelf-life, shall be labeled specifically for the LICENSEE, and shall be ready for end-user sale, including all packaging,
labeling, and instructions-for-use, as agreed between the parties always provided KREUSSLER has consented to such packaging, labeling, instructions-for-use and other characteristics in writing in advance, which consent shall not be unreasonably
withheld, and further provided all such characteristics are in accordance with any applicable regulatory requirements. 

 The LICENSEE will develop and implement packaging and labeling for PRODUCT(S), subject to applicable regulatory requirements and consent of KREUSSLER. Unless otherwise required by applicable regulatory requirements, changes to the packaging
and labeling for a particular PRODUCT may only be proposed from the LICENSEE to KREUSSLER in intervals greater than six (6) months. 
 KREUSSLER shall ensure that all PRODUCT(S) shall be labeled in accordance with the procedures specified from time to time by the LICENSEE and the LICENSEE shall have final approval over the production (printing) of all secondary packaging
and labeling material for PRODUCT(S), except for the consent provided for in the immediately preceding sentence. 
  

	 	p)	Acceptance. 

  

	 	i)	Each shipment of PRODUCT(S) from KREUSSLER to the LICENSEE shall contain such quality control certificates reasonably requested by the LICENSEE certifying that the PRODUCT(S) UNITS
shipped conform to the PRODUCT SPECIFICATIONS. 

  

	 	ii)	Notwithstanding any prior inspection or payments, all PRODUCT(S) will be subject to final inspection and acceptance at the LICENSEE’s designated destination point within
fifteen (15) business days after delivery. The LICENSEE shall notify KREUSSLER by e-mail or facsimile followed by a confirmation sent via courier within fifteen (15) business days after delivery of any apparent defective material or
workmanship or non-conformity of any PRODUCT(S) UNIT to the PRODUCT SPECIFICATIONS or purchase order. If the LICENSEE fails to so notify KREUSSLER, the LICENSEE will be deemed to have accepted the PRODUCT(S) UNITS received and waived its right to
revoke acceptance. 

  

	 	iii)	If the LICENSEE believes any PRODUCT(S) UNIT shipped does not conform to the PRODUCT SPECIFICATIONS, it shall provide KREUSSLER with a detailed explanation of the non-conformity.

 Upon receipt, KREUSSLER will investigate such alleged non-conformity, and 
  

	 	(a)	if KREUSSLER agrees such PRODUCT(S) UNIT is non-conforming, deliver to the LICENSEE a corrective action plan within fifteen (15) business days after receipt of the
LICENSEE’s 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 25 - 

	 	 
written notice of non-conformity, or such additional time as is reasonably required if such investigation or plan requires data from sources other than the
LICENSEE or KREUSSLER, or 

  

	 	(b)	if KREUSSLER disagrees with the LICENSEE’s determination that the PRODUCT(S) UNIT is non-conforming, KREUSSLER shall so notify the LICENSEE by e-mail or fax within fifteen
(15) business days after receipt of the LICENSEE’s written notice of non-conformity and confirm such notice in writing by overnight delivery. 

  

	 	iv)	If, following KREUSSLER’S notification pursuant to paragraph (iii) (b) above, the parties continue to dispute whether a PRODUCT(S) UNIT is conforming or
non-conforming to the PRODUCT SPECIFICATIONS, such PRODUCT(S) UNIT shall be submitted to a mutually accepted laboratory or, in the absence of such mutual acceptance, to the Zentrallaboratorium Deutscher Apotheker, 65760 Eschborn, Germany, for
resolution, whose determination of conformity or non-conformity and the cause thereof shall be binding upon the parties. 

  

	 	v)	In the event KREUSSLER pursuant to paragraph (iii) (a) above agrees that the PRODUCT(S) UNIT is non-conforming or the laboratory pursuant to paragraph (iv) above
determines that the PRODUCT(S) UNIT is non-conforming, KREUSSLER shall replace such non-conforming PRODUCT(S) UNIT within sixty (60) calendar days after receipt of a respective notice from the laboratory or, as the case may be, notification of
KREUSSLER to the LICENSEE of its acceptance of such non-conformity. The LICENSEE shall return to KREUSSLER or, at KREUSSLER’s sole discretion, destroy or have destroyed all non-conforming PRODUCT(S) UNITS. 

  

	 	vi)	In the event KREUSSLER agrees, or the laboratory determines, that a PRODUCT(S) UNIT is non-conforming solely as a result of the negligence or willful misconduct of KREUSSLER or its
AFFILIATE or contract manufacturer, KREUSSLER shall bear the cost for replacing such PRODUCT(S) UNIT, including any cost of production, and, to the extent applicable, shall bear the costs of the laboratory and the return or destruction of the
non-conforming PRODUCT(S) UNIT. 

  

	 	vii)	In all other events, the LICENSEE shall pay for all PRODUCT(S), including replacement PRODUCT and shall bear the costs of the laboratory and, for the avoidance of doubt, shall pay
also for such quantities of PRODUCT(S) that have been used up during laboratory testing and the return or destruction of the rejected PRODUCT(s). 

  

	 	q)	 KREUSSLER shall not make any changes to the PRODUCT(S) (including materials, packaging, and directions for use), the PRODUCT SPECIFICATIONS, raw materials, or
manufacturing process for the PRODUCT(S), which in any case could reasonably be expected to affect the form, function, regulatory status, or 

  

 - 26 - 

	 	 
efficacy of the PRODUCT(S) or patient safety, unless approved by the LICENSEE in writing in advance, which approval shall not be unreasonably withheld or
delayed. 

 Without limiting the foregoing, all such changes (including changes required by law) shall be submitted to the
LICENSEE no later than sixty (60) calendar days prior to KREUSSLER’S proposed date of implementation for such change. Unless the LICENSEE notifies KREUSSLER in writing that it disapproves of such change during the sixty (60) calendar
day period or if such a proposed change is otherwise required by law, regulation, or REGULATORY AUTHORITY directive, KREUSSLER shall be authorized to implement such change and shall be responsible for properly communicating and implementing such
change, including with respect to any of KREUSSLER’s vendors. 
 Without limiting the foregoing, the following changes shall be deemed
governed by this section: 
  

	 	i)	use of any nonconforming material in the manufacture of any PRODUCT(S) in variance with the PRODUCT SPECIFICATIONS; 

  

	 	ii)	implementation of any KREUSSLER-authorized temporary deviation that could affect the handling, sterility, safety, or efficacy of any PRODUCT(S) and be at variance with the PRODUCT
SPECIFICATIONS; or 

  

	 	iii)	implementation of any KREUSSLER-initiated corrective action that could affect the safety or efficacy of the PRODUCT(S). 

 The foregoing is not intended to limit KREUSSLER’S ability to make changes to any product other than the PRODUCT(S) (or any of its components).

  

	 	r)	KREUSSLER will notify the LICENSEE immediately in writing upon becoming aware of any material obsolescence (Überalterung), supply shortage, or other interruption or
potential interruption in the supply of any material, component, or sub-assembly, in each case as it could reasonably be expected to affect the supply of the PRODUCT(S) according to this Article VII. If KREUSSLER becomes or projects that it may be
incapable of making such required deliveries of PRODUCT(S), subject to normal lead-time requirements, KREUSSLER agrees to meet with the LICENSEE and agrees to a reasonable allocation plan to assure the LICENSEE a fair allocation of KREUSSLER
resources to meet the LICENSEE’S requirements for PRODUCT(S). 

  

	 	s)	All quantities of PRODUCT(S) delivered pursuant to the terms of this AGREEMENT shall be delivered to the LICENSEE’S address stated on the first page hereof or such other place
of delivery as designated by the LICENSEE from time to time. Shipping terms shall be ex works KREUSSLER’S address stated on the first page hereof or, at the choice of KREUSSLER, the manufacturing facilities for the PRODUCT(S), as defined in
INCOTERMS 2000. Place of fulfillment shall be KREUSSLER, Wiesbaden, Germany. 

  

 - 27 - 

 Article VIII – DOWN PAYMENT and ROYALTY 
  

	 	a)	In consideration of the licenses, rights and interest granted under this AGREEMENT and as a remuneration for the expenses incurred by KREUSSLER for obtaining those REGISTRATIONS for
the PRODUCT(S), including marketing authorization by the FDA, the LICENSEE shall pay to KREUSSLER 

  

	 	i)	Within ten (10) business days from the date of the SUCCESSFUL TRANSITION DATE the sum of [****] such sum being non refundable once made; 

  

	 	ii)	Within [****] from the EFFECTIVE DATE of this AGREEMENT the sum of [****], such sum being not refundable once made; 

  

	 	iii)	Within ten (10) business days following receipt of notification [****] that the documentation [****] based upon [****] (as defined in VIII (b) below) of the clinical trial
(EASI STUDY), the sum of [****], such sum being not refundable once made; 

  

	 	iv)	Within ten (10) working days following receipt of notification by KREUSSLER that [****] for the PRODUCT(S) in the TERRITORY has been [****] (accompanied by a copy of [****] the
sum of [****], such sum being not refundable once made; 

  

	 	v)	An amount of [****] one calendar year following the notification in [****] sum being not refundable once made; 

  

	 	vi)	The down payment in Article VIII (a) (iv) and (v) will be reduced by the sum of [****] each, if a [****], as defined in Article III (b) is requested by the FDA.

  

	 	vii)	During the term of this AGREEMENT, forty five (45) days following the end of every QUARTER, a [****] amounting to [****] of the LICENSEE’S NET SALES of the PRODUCT(S) in
such QUARTER, subject to Articles VI (b) (ii) and (iv). 

  

	 	b)	For the purposes of Article VIII (a) (iii), [****] will be defined as the EASI STUDY 

  

	 	i)	[****] 

  

	 	ii)	[****] In the event that this subparagraph (ii) applies the payment pursuant to Article VIII (a) (iii) shall become due at the latest together with the payment
pursuant to Article VIII (iv). 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 28 - 

	 	c)	All amounts referred to in this AGREEMENT are net and do not include VAT, if any. All amounts shall be paid to a bank account to be designated by KREUSSLER in Germany.

 Article IX – SECRECY 
  

	 	a)	Each party (the “RECIPIENT”) hereby undertakes to maintain any and all “CONFIDENTIAL INFORMATION” hereunder or hereinafter supplied by the other party (the
“DISCLOSER”) in strictest confidentiality, to use it only for the purposes of this AGREEMENT and to disclose same only to its employees, outside consultants and institutes who have a need to become privy to it in order to fulfill the
purpose hereof and only provided each of those recipients has entered into a written confidentiality undertaking at least as stringent as provided for in this AGREEMENT. The RECIPIENT shall also be entitled to disclose the information to the
competent authorities in the TERRITORY to the extent required to apply for and obtain any REGISTRATION and the maintenance thereof. The RECIPIENT shall take all such appropriate measures to safeguard the information from any unauthorized disclosure
and/or use. 

  

	 	b)	Each party undertakes not to publish or cause to be published any information or any tests, studies or results obtained with or in relation to the PRODUCT(S), including information,
tests, studies or results obtained in the conduct of clinical trials or post marketing studies conducted or directly controlled by either party, without having first obtained the written consent of the other party to such publication, such consent
not to be unreasonably withheld or delayed. 

  

	 	c)	Notwithstanding anything to the contrary in the foregoing paragraphs, RECIPIENT shall not be deemed to have breached its confidentiality obligation if RECIPIENT can establish by
written records that: 

  

	 	i)	the information was, at the time of disclosure by RECIPIENT, in the public domain; 

  

	 	ii)	the information has, subsequent to disclosure by RECIPIENT, become part of the public domain through no fault, act, omission or violation by RECIPIENT of the confidentiality
obligation; 

  

	 	iii)	the information was, at the time of disclosure by DISCLOSER, in the possession of RECIPIENT and not otherwise acquired, directly or indirectly, from DISCLOSER; and/or

  

	 	iv)	the information has, subsequent to disclosure by DISCLOSER, been obtained by RECIPIENT from any other party, provided, however, that it was not obtained by said third party,
directly or indirectly, from DISCLOSER. 

  

 - 29 - 

	 	d)	Notwithstanding anything to the contrary in this AGREEMENT, the confidentiality obligations shall survive expiration or termination hereof for any reason whatsoever.

 Notwithstanding the provisions of Article IX (a) above, each party may disclose CONFIDENTIAL INFORMATION of the other
party to its AFFILIATES, and, upon prior written consent by such other party, which shall not be unreasonably withheld, to other third parties to the extent such disclosure is reasonably necessary to 
  

	 	•	 	 exercise the rights granted to it, or reserved by it, under this AGREEMENT, 

  

	 	•	 	 prosecuting or defending litigation, 

  

	 	•	 	 complying with applicable governmental laws or regulations, 

  

	 	•	 	 submitting information to tax or other governmental authorities or 

  

	 	•	 	 conducting clinical trials hereunder with respect to a PRODUCT, provided that in the event of the LICENSEE conducting clinical trials hereunder the parties have
mutually agreed to the LICENSEE conducting such clinical trials. 

  

	 	e)	Where the disclosing party is required by law or regulations to make any such disclosure of the CONFIDENTIAL INFORMATION of the other party within such period of time that does not
reasonably allow it to obtain the prior written consent by such other party, it will use its good faith efforts to secure confidential treatment of such confidential information prior to its disclosure (whether through protective orders or
otherwise) and will give notice of such disclosure to such other party immediately after such disclosure was made. For any other disclosures of the CONFIDENTIAL INFORMATION of the other party, including to AFFILIATES, the disclosing party shall
ensure that the recipient thereof is bound by a written confidentiality undertaking at least as stringent as provided for in this AGREEMENT. In addition, each party may disclose the terms of this AGREEMENT to advisors (including financial advisors,
attorneys and accountants), actual or potential acquisition partners or private investors on a need to know basis, in each case under the confidentiality provisions substantially equivalent to those in this AGREEMENT unless the receiving party is
subject to a professional secrecy obligation resulting from legal obligations or mandatory professional rules. 

  

	 	f)	Prior Non-Disclosure Agreements. Upon execution of this AGREEMENT, the terms of this Article IX shall supersede any prior non-disclosure, secrecy or confidentiality agreement
between the parties. The foregoing notwithstanding, any information disclosed under such prior agreements shall remain subject to the terms of such prior agreements. 

  

 - 30 - 

 Article X – LIABILITY 
  

	 	a)	Each party will comply with all laws and regulations in the TERRITORY applicable to it that pertain to the testing, manufacture, labeling, marketing, storage, warehousing,
distribution, sale, or packaging of the PRODUCT(S) and in any other manner pertaining to the performance of its obligations under this AGREEMENT, including the maintenance of ongoing quality assurance and testing procedures to comply with applicable
regulatory requirements. 

 Without limiting the foregoing, as between the parties, it is the responsibility of the LICENSEE to
ensure that the marketing, storage, warehousing, distribution and sale of the PRODUCT(S) is done in compliance with all applicable laws and regulations and it is also the responsibility of the LICENSEE to ensure that all marketing and sales
activities accurately represent the indications, package insert and other labeling of the PRODUCT(S) and the LICENSEE shall indemnify and hold KREUSSLER harmless for any activities by the LICENSEE and its AFFILIATES which are outside the scope of
any applicable laws and regulations in the TERRITORY. 
  

	 	b)	Indemnity by KREUSSLER: KREUSSLER shall defend, indemnify and hold the LICENSEE, its directors, officers and employees, harmless from and against any and all claims, suits or
demands for liability, damages, losses, costs and expenses (including the costs and expenses of attorneys and other professionals) arising out of third-party claims or suits or demands based on alleged or actual bodily injury or property damage
resulting from: 

  

	 	i)	the manufacture of the PRODUCT(S) 

  

	 	ii)	clinical studies conducted by or on behalf of KREUSSLER prior to REGISTRATION of the PRODUCT(S) and 

  

	 	iii)	the use or sale of the PRODUCT(S) by KREUSSLER, its AFFILIATES or its licensees outside the TERRITORY and any legal action for patent infringement brought against the LICENSEE or
its AFFILIATES with respect to the PRODUCT(S). 

  

	 	c)	Indemnity by the LICENSEE: The LICENSEE shall defend, indemnify and hold KREUSSLER, its directors, officers and employees, harmless from and against any and all claims, suits or
demands for liability, damages, losses, costs and expenses (including the costs and expenses of attorneys and other professionals) arising out of third-party claims or suits or demands based on alleged or actual bodily injury or property damage
resulting from 

  

	 	i)	the importation, use, storage, distribution or sale of the PRODUCT(S) by the LICENSEE or its sublicensees or AFFILIATES and 

  

	 	ii)	clinical studies conducted by or on behalf of the LICENSEE prior to REGISTRATION. 

  

 - 31 - 

	 	d)	Mutual Indemnity: In addition to Articles X (a) and X (b), each party (“Indemnifying Party”) shall defend, indemnify and hold the other party (“Indemnified
Party”) and its directors, officers and employees (the “Indemnitees”) harmless from and against any and all third-party claims, suits, and demands for liability, damages, losses, costs and expenses (including the reasonable costs and
reasonable expenses of attorneys and other professionals) arising out of or resulting from the alleged or actual inaccuracy of any representation or the breach by the Indemnifying Party of any warranty or covenant contained in this AGREEMENT.

  

	 	e)	Conditions of Indemnification: In the event that any party hereunder seeks indemnification under this Article X, such party shall: 

  

	 	i)	promptly inform the Indemnifying Party of any claim, suit or demand threatened or filed, 

  

	 	ii)	permit the Indemnifying Party to assume direction and control of the defense of claims resulting therefrom (including the right to settle such claims at the sole discretion of the
Indemnifying Party, but subject to the approval of the other party, not to be unreasonably withheld, and 

  

	 	iii)	cooperate as requested (at the expense of the Indemnifying Party) in the defense of such claims. 

  

	 	f)	Limits of Indemnity: An Indemnifying Party’s obligations under this Article X shall not extend to any claims, suits or demands for liability, damages, losses, costs and
expenses to the extent arising from the Indemnified Party’s failure to comply with the terms and conditions of this AGREEMENT or to the extent arising from the negligence or willful misconduct of the Indemnified Party or Indemnitee, its agents
or employees. No party shall be liable under any provision of this AGREEMENT for any punitive, exemplary, multiplied or consequential damages. 

 Article XI – TERM AND TERMINATION 
  

	 	a)	The coming into force of this AGREEMENT shall be conditional (aufschiebende Bedingung) upon KREUSSLER having successfully terminated the currently existing conflicting
Licensing and Distribution Agreement for the PRODUCT(S) in the TERRITORY between KREUSSLER and a third party distributor (the “CONFLICTING AGREEMENT”), with no ongoing obligation to such third party that could become a liability for
LICENSEE (the “SUCCESSFUL TRANSITION DATE”). KREUSSLER shall use best commercially reasonable efforts to terminate such agreement within ninety (90) days of the EFFECTIVE DATE and to inform the LICENSEE of such termination without
delay. Without prejudice to the general secrecy obligations set forth in Article IX, each party undertakes to keep strictly confidential and not to communicate in any form to any third party, the negotiation, execution and existence of this
AGREEMENT until the SUCCESSFUL TRANSITION DATE has occured. Once it has come into force this AGREEMENT shall run for twelve (12) years from the day on which the first REGISTRATION has been granted for the first PRODUCT in the TERRITORY (herein
defined as INITIAL TERM). 

  

 - 32 - 

 This AGREEMENT shall automatically be renewed for further periods of three (3) years, subject to the
provisions concerning the achievement of the minimum annual purchase volumes, unless either party serves written notice to the other informing it of its decision to terminate this AGREEMENT at least eleven (11) months prior to the expiration of
the INITIAL TERM or any subsequent term. 
 The foregoing notwithstanding, the SUCCESSFUL TRANSITION DATE, shall only be deemed to have
occurred upon written notice by KREUSSLER to LICENSEE that the CONFLICTING AGREEMENT has been terminated, with no ongoing obligation or liability that could be incurred by LICENSEE as the result of such termination. Written notice by KREUSSLER of
the occurrence of the SUCCESSFUL TRANSITION DATE shall be deemed a representation and warranty by KREUSSLER that such required termination is valid and that no ongoing obligation or liability could be incurred by LICENSEE as the result of such
termination. 
  

	 	b)	During the INITIAL TERM and any subsequent term hereof, this AGREEMENT may be terminated as provided by law or otherwise provided in this AGREEMENT, and in accordance with the
following provisions: 

  

	 	i)	Except in the event of FORCE MAJEURE pursuant to Article XIII (d) hereof, by either party with [****] written notice (termination notice) should the other party not have cured
a material breach or material default of its obligations under this AGREEMENT within [****] from the notice (breach notice) stating such breach or default of compliance; 

 provided, that if the breaching or defaulting party is undertaking good faith efforts to cure such breach or default at the end of such [****] period,
then such [****] period shall be extended to [****] by another [****] or such other additional period mutually agreed in writing between the parties. 
 At the end of the [****] period or such other mutually agreed additional period, if the breaching party has not cured its breach, the AGREEMENT may be terminated with immediate effect. At the option of the
non-breaching party, such termination may be with respect to the entire AGREEMENT, or only with respect to the respective PRODUCT(S) which is subject of the breach. 
  

	 	ii)	By either party with immediate effect should the other party file an application for insolvency, should insolvency proceedings be initiated or not initiated due to a lack of assets,
should the other party enter into an agreement for the assignment of assets for the benefit of creditors, wind-up, be nationalized, enter into liquidation or otherwise cease to conduct its business as heretofore conducted. 

 

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 33 - 

 Article XII – EFFECT OF TERMINATION 
  

	 	a)	In addition to any other provisions herein stipulated as to the effect of termination or expiration, the LICENSEE shall, upon expiration or termination for any reason whatsoever:

  

	 	i)	immediately cease to market and sell the PRODUCT(S), except as described below; 

  

	 	ii)	immediately return to KREUSSLER, without retaining any copy, any and all information received from KREUSSLER as well as all remaining SAMPLES, sales promotion or training material
and other material put at the disposal of the LICENSEE by KREUSSLER. The LICENSEE hereby expressly renounces to any right or claim of retention thereon for any reason whatsoever; 

  

	 	iii)	as directed by KREUSSLER, 

  

	 	(a)	either cancel any REGISTRATION(S), any clinical trial certificate and other administrative files, such as but not limited to the price certificates, authorizations, reimbursement
authorization, import license and/or quotas, or 

  

	 	(b)	take all steps necessary, including notifications and announcements, to secure free of charge the prompt transfer of any relevant REGISTRATION(S) to KREUSSLER or its nominee.
KREUSSLER will bear possible administrative fees. 

  

	 	iv)	not be relieved from performing any obligation which may have arisen or accrued prior to the effective date of termination or expiration hereof. 

 KREUSSLER may, but does not have the obligation, to purchase or cause to be repurchased any stock of PRODUCT(S) which the LICENSEE might have at the
effective date of termination or expiration at a price which shall be the effective cost thereof to the LICENSEE. 
  

	 	b)	Should KREUSSLER decide not to purchase the stock of PRODUCT(S), in case of termination by KREUSSLER within two (2) weeks after sending notice of termination to the LICENSEE,
or, in case of termination by the LICENSEE within two (2) weeks after receipt of such notice of termination by the LICENSEE, the LICENSEE shall use commercially reasonable efforts to sell or dispose of all stocks prior to the effective date of
termination of this AGREEMENT. Should nevertheless the LICENSEE still hold stock of PRODUCT(S), KREUSSLER shall grant the LICENSEE an extension of not more than six (6) months to dispose of unsold stocks. Any stock not disposed of after such
extension period shall be destroyed by the LICENSEE at its cost. 

  

 - 34 - 

	 	c)	Termination or expiration of this AGREEMENT shall not relieve the parties of any obligation or liability accruing prior to such termination or expiration. Any accrued obligation or
liability and the provisions of Articles IV (j) and (k), IX, and any other Article the subject matter of which extends beyond the term of this AGREEMENT shall survive termination or expiration of this AGREEMENT. Neither party shall have any
claims for compensation against the other party (e.g. for any goodwill created or other continuous benefits of the other party resulting from the performance of this AGREEMENT) that result solely from termination or expiration of this AGREEMENT;
however, this sentence does not relieve either party from any obligations or liability accruing from a breach of this AGREEMENT (e.g., if the AGREEMENT is terminated due to breach of this AGREEMENT, this sentence does not relieve the breaching party
from liability resulting from that breach). Upon termination each party shall either return or destroy, upon the request of the other party, all forms of confidential information received from the other party, (or the confidential information
pertaining to the terminated license), retaining only one copy, or such other quantity as required under any applicable law or regulation, of written or electronic confidential information for archival, regulatory or legal purposes.

 Article XIII – GENERAL PROVISIONS 
  

	 	a)	This AGREEMENT cannot be amended in any respect except by an instrument in writing duly executed by authorized representatives of both parties. No waiver of compliance with any
provision or condition hereof and no consent herein provided for shall be effective unless evidenced by an instrument in writing duly executed by authorized representatives of the party sought to be charged with such waiver or consent.

  

	 	b)	Nothing herein contained shall be deemed to create the relationship of principal and agent, each party acting as an independent business enterprise. 

  

	 	c)	The correspondence languages shall be English and at the discretion of the LICENSEE German. All notices and communications to be given or permitted hereunder shall be in English and
sent by facsimile, or by registered mail at the respective addresses hereinabove stipulated or at such other address as may be notified by either party to the other. 

  

	 	d)	Neither party shall be liable for failure to perform any obligation hereunder if such failure is due to FORCE MAJEURE, that is circumstances beyond the reasonable control of said
party or any of its subcontractors such as but not limited to fire, flood, act of God, governmental regulations, acts of any competent authority, strikes, riots or the like, shortage of [****] due to reasons other than KREUSSLER’s unreasonable
scheduling of stock (failure by KREUSSLER to maintain at least [****] of stock prior to the [****] supply interruption shall be considered unreasonable), provided, however, that this shall not relieve either party from performing its obligations
hereunder at such time and to such extent as may be possible subsequent to the intervention of the above cited events or occurrences. 

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 35 - 

	 	e)	The failure by either party to exercise or enforce any right conferred upon it hereunder shall not be deemed to be a waiver of any such rights nor operate to bar the exercise or
enforcement thereof at any time or times thereafter. 

  

	 	f)	The English version of this AGREEMENT shall be governing. The title of Articles are inserted for convenience purposes only and shall not be used in the interpretation of this
AGREEMENT. 

  

	 	g)	Should any provision of this AGREEMENT be declared null and void in whole or in part, this shall not have as an effect to terminate this AGREEMENT and the parties shall negotiate in
good faith and replace such provision reflecting as nearly as possible the intent and purpose of such provision. The same applies in the case of an omission in this AGREEMENT. 

  

	 	h)	The parties acknowledge and agree that: (i) each party and its counsel reviewed and negotiated the terms and provisions of this AGREEMENT and has contributed to its revision;
(ii) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be employed in the interpretation of this AGREEMENT; and (iii) the terms and provisions of this AGREEMENT shall be construed
fairly as to all parties hereto generally responsible for the preparation of this AGREEMENT. 

  

	 	i)	Except as set forth in the next sentence, this AGREEMENT, or any of the rights and obligations created herein, shall not be assigned or transferred, in whole or in part, by either
party hereto unless 

 (i) the other party has provided its prior written consent, and 
 (ii) the assignee unconditionally agrees in writing that the terms of this AGREEMENT shall be a binding obligation of the assignee. 
 Without prejudice to the generality of the foregoing, each party shall have the right to assign this AGREEMENT without such prior consent of the other
party 
 (i) to any AFFILIATE, or 
 (ii) to any successor of all or substantially all of its business (or that portion thereof to which this AGREEMENT relates), or 
 (iii) to any successor in the event of such party’s merger, consolidation or involvement in a similar transaction; 
 each
provided that such AFFILIATE or successor is not a COMPETITOR of the other party, and, provided further, such AFFILIATE or successor unconditionally agrees in writing that the terms of this AGREEMENT shall be a binding obligation of such AFFILIATE
or successor. 
  

	 	j)	During the term of this AGREEMENT, if KREUSSLER agrees to a final unexecuted agreement by which: 

  

	 	i)	a merger, acquisition, sale or other disposition of all or substantially all of KREUSSLER’s business, or 

  

 - 36 - 

	 	ii)	the sale or other disposition of all or substantially all of KREUSSLER’s assets directly related to the manufacturing of the PRODUCT(S) 

 to a COMPETITOR of the LICENSEE or other competitor of the LICENSEE (i.e. either a third-party competitor of LICENSEE in any market or a third party with
the obvious intention upon concluding such agreement not to fulfill the obligations hereunder) would be concluded, THE LICENSEE shall have the first right of refusal to acquire such assets and/or business. Upon agreeing to final terms of such
agreement with a third party, KREUSSLER shall first offer the terms to the LICENSEE and the LICENSEE shall have fifteen (15) business days to accept these terms, execute the final agreement and finalize the transaction. If the LICENSEE does not
accept these terms and/or does not execute the final agreement within the fifteen (15) business days period, KREUSSLER shall be free to proceed with the proposed transaction with the third party on essentially the same terms as presented to the
LICENSEE. 
 Article XIV – APPLICABLE LAW, ARBITRATION 
  

	 	a)	This AGREEMENT shall be interpreted and construed in accordance with the laws of GERMANY specifically excluding its conflict of law provisions, the UN-Convention on Contracts for
the International Sale of Goods and the application of any other uniform civil or conflict of law rules created by intergovernmental or inter-State Conventions or Treaties or multilateral Pacts. 

  

	 	b)	All disputes arising out of or in connection with this AGREEMENT and which could not be amicably settled by the parties within sixty (60) days from the notice of any such
dispute shall be settled by arbitration under the Rules of Arbitration of the International Chamber of Commerce (Paris, France) (“ICC-Rules”) by three arbitrators – provided that the parties cannot agree on one arbitrator –
appointed in accordance with the said ICC-Rules. The venue of arbitration shall be Basel, Switzerland, should the parties not agree on a different venue of arbitration. It shall be ensured that the arbitrators, by accepting appointment, undertake to
exert their best efforts to conduct the process so as to issue an award within nine months of the appointment of the last arbitrator. The arbitrators shall decide the Dispute in accordance with the law governing this AGREEMENT. The award of the
arbitrators shall be final and binding and may be entered in any court of competent jurisdiction. 

  

	 	c)	From the date of initiation of arbitration and until such time as any matter has been finally settled by arbitration in accordance with this section, the running of the time periods
contained in Article XI as to which party must cure an alleged breach of this AGREEMENT shall be suspended as to the subject matter of the dispute. 

  

	 	d)	Each party may initiate any interim or conservatory measures (e.g. apply for a preliminary injunction) as provided for in Article 23 (2) of the ICC-Rules.

  

 - 37 - 

 IN WITNESS HEREOF, the parties have caused this AGREEMENT to be executed by their authorized
representatives as of the date first above written in duplicate originals, each with the same force and effect. 
  

													
	 Chemische Fabrik
 Kreussler
& Co. GmbH
	 		  		  		  	 LICENSEE
 BioForm Medical,
Inc.

					
	 /s/ Dr. S. Travers
	 		  	 /s/ Dr. C. Freyberg
	  		  	 /s/ Steven L. Basta

	 Dr. S. Travers
 Managing
Director
	 		  	 Dr. C. Freyberg
 International
Marketing
 & Sales Director
 Pharmaceutical
Division
	  		  	 Steven L. Basta
 President
& CEO

							
	Wiesbaden,	 		 		  	 May 11, 2007
	  		  	San Mateo, CA	  	 May 11, 2007

		 		 		  	        Date	  		  		  	        Date

  

 - 38 - 

 Annex I to the Licensing and Distribution Agreement dated May 11, 2007 
 between BioForm Medical Inc. and Chemische Fabrik KREUSSLER & Co. GmbH 
 PROPRIETARY MEDICINAL PRODUCTS 
  

							
	 Product
	  	 Composition
	  	 Presentation/Unit
	  	 Registration No.

	 Aethoxysklerol 0.5%
	  	(5 mg/ml polidocanol)	  	[****]	  	registration pending
	 Aethoxysklerol 1%
	  	(10 mg/ml polidocanol)	  	[****]	  	registration pending

  

													
	 Chemische Fabrik
 Kreussler
& Co. GmbH
	 		  		  		  	 LICENSEE
 BioForm Medical,
Inc.

					
	 /s/ Dr. S. Travers
	 		  	 /s/ Dr. C. Freyberg
	  		  	 /s/ Steven L. Basta

	 Dr. S. Travers
 Managing
Director
	 		  	 Dr. C. Freyberg
 International
Marketing
 & Sales Director
 Pharmaceutical
Division
	  		  	 Steven L. Basta
 President
& CEO

							
	Wiesbaden,	 		 		  	 May 11, 2007
	  		  	San Mateo, CA	  	 May 11, 2007

		 		 		  	        Date	  		  		  	        Date

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 39 - 

 Annex II to the Licensing and Distribution Agreement dated May 11, 2007 
 between BioForm Medical Inc. and Chemische Fabrik KREUSSLER & Co. GmbH 
 MINIMUM ANNUAL QUANTITIES 
 The LICENSEE guarantees to purchase the following minimum UNITS of each of the PRODUCT(S)
in each Year (excluding SAMPLES): 
  

									
	 Product / UNITS
	  	Year 1	  	Year 2	  	Year 3	  	Year 4
	 Aethoxysklerol 0.5%
	  	[****]	  	[****]	  	[****]	  	[****]
	 Aethoxysklerol 1%
	  	[****]	  	[****]	  	[****]	  	[****]

 PRICES 
 The
transfer price for which KREUSSLER will sell the PRODUCT(S) to the LICENSEE will be the greater of: 
  

											
	 	  	 	  	 	  	 	  	Year 1- 5	  	Year 6+
	 1 UNIT
	  	Aethoxysklerol 0.5%	  	[****]	  	USD	  	[****]	  	[****]
	 1 UNIT
	  	Aethoxysklerol l%	  	[****]	  	USD	  	[****]	  	[****]

 Or 
  

					
	 Per concentration
	  	 Year 1-3
	  	 Year 4 and beyond.

	[****]	  	[****] of ASP	  	[****] of ASP
			
	 [****]
	  	 [****] of ASP
 for those quantities exceeding
 minimum annual purchase
 quantities
	  	 [****] of ASP
 for those quantities
 exceeding minimum annual
 purchase quantities

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 40 - 

 EXPORT UNIT 
  

							
		 	1 cardboard-box	  	contains [****]
			
		 	Small:	  	one-way-pallet at least consisting of [****] cardboard-boxes:
		 		  	 measurement:        [****]
	  	
			
		 	Big:	  	one-way-pallet at least consisting of [****] cardboard-boxes:
		 		  	 measurement:        [****]
	  	
			
		 	 Minimum quantity per
 order:
	  	[****]
			
		 	Prices:	  	Are to be understood ex works, packing included, insurance and duties unpaid
			
		 	Payment:	  	45 (forty-five) days after date of invoice by remittance or cheque.
			
		 	Place of fulfillment:	  	As defined in Article VII (s)
			
		 	 Regulatory / Other
 Fees:
	  	 The LICENSEE will be responsible for fees, taxes,
 duties and further levies following US FDA approval

  

													
	 Chemische Fabrik
 Kreussler
& Co. GmbH
	 		  		  		  	 LICENSEE
 BioForm Medical,
Inc.

					
	 /s/ Dr. S. Travers
	 		  	 /s/ Dr. C. Freyberg
	  		  	 /s/ Steven L. Basta

	 Dr. S. Travers
 Managing
Director
	 		  	 Dr. C. Freyberg
 International
Marketing
 & Sales Director
 Pharmaceutical
Division
	  		  	 Steven L. Basta
 President
& CEO

							
	Wiesbaden,	 		 		  	 May 11, 2007
	  		  	San Mateo, CA	  	 May 11, 2007

		 		 		  	        Date	  		  		  	        Date

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 41 - 

 Annex III to the Licensing and Distribution Agreement dated May 11, 2007 
 between BioForm Medical Inc. and Chemische Fabrik KREUSSLER & Co. GmbH 
 As a detailed description of Article III (h) of the said AGREEMENT, this annex defines the responsibilities for the TERRITORY related post marketing safety reporting and recordkeeping for the preparation defined
in appendix 1 between: 
 Chemische Fabrik KREUSSLER & Co. GmbH, 
 Rheingaustrasse 87-93, 65203 Wiesbaden, Germany 
 hereinafter referred to as “KREUSSLER” 
 and 
 BioForm Medical, Inc. 
 1875 S. Grant Street, #110, 
 San Mateo, CA 94402 
 hereinafter referred to
as “LICENSEE” 
 The LICENSEE agrees by signing this contractual agreement to take over TERRITORY-related pharmacovigilance responsibilities for
the PRODUCT(S) in accordance with current TERRITORY regulations as specified under Appendix 2. 
 This includes but is not restricted to the following
provisions: 
  

	1.)	Nomination of a responsible person for pharmacovigilance (QPP) 

 The LICENSEE shall appoint a responsible person for pharmacovigilance (“Qualified person for pharmacovigilance” (QPP) or “pharmacovigilance officer” or “head of pharmacovigilance”) with the necessary and
requisite educational and professional experiences in the TERRITORY-pharmacovigilance procedures who shall fulfill all TERRITORY-related pharmacovigilance responsibilities for LICENSEE. A deputy with similar experience must be appointed also. It is
possible that the LICENSEE nominates external pharmacovigilance officers who are obliged by a written agreement to act on behalf of themselves. Curricula vitae must be available at the LICENSEE. Where required by TERRITORY regulations the QPP and
his deputy shall be officially nominated by the LICENSEE to the competent TERRITORY REGULATORY AUTHORITY. 
 The LICENSEE shall draft a job
description for each of these positions and shall submit such description to KREUSSLER, along with copies of the curricula vitae. KREUSSLER has the right to object the nomination of such persons should KREUSSLER regard the expertise as insufficient
to comply with the legal requirements, such objection shall however not be made without good cause. The LICENSEE shall declare the initial nomination and any subsequent change in personnel in writing to KREUSSLER immediately hereafter and if
necessary to the relevant authority. 

	2.)	Cooperation with KREUSSLER’s responsible persons 

 The
LICENSEE’s QPP shall work in co-ordination with KREUSSLER’s responsible person for pharmacovigilance or his deputy, KREUSSLER’s world-wide pharmacovigilance activities and the responsible person(s) for pharmacovigilance data
management. All communications unless specified otherwise shall be sent to the person responsible for the pharmacovigilance data management. The names of these persons are laid down in Appendix 3 of this agreement. 
  

	3.)	Standard operating procedures 

 The LICENSEE shall work
according to written standard operating procedures (SOPs) for reporting and recordkeeping of all post marketing adverse drug experiences (herein defines as ADEs) which is recognized as a synonym to adverse drug reaction (ADR). Copies of these SOPs
must be provided to KREUSSLER. 
  

	4.)	Review of ADEs 

 ADEs according to 21CFR314.80 or such
other relevant regulation for the TERRITORY, from any source, domestic or foreign, obtained or otherwise received by any employee of the LICENSEE shall promptly be reviewed by the LICENSEE’s QPP. This applies also to reports in the scientific
literature. 
  

	5.)	Classification of ADEs 

 LICENSEE shall classify each ADE.

 Classification criteria are: 
 a.) serious (s) or non serious (n) and 
 b.) expected/known (k) or unexpected/unknown
(u). 
 c.) causality: certain, probable (A), possible (B) or unlikely, unassessable (O) 
 Unless otherwise provided by mandatory TERRITORY laws and regulations, the basis for “serious” shall be ICH-guideline E2A, for
“expectedness” the current TERRITORY-labeling text {or Summary of Product Characteristics} and for the causality assessment the classification of “Causality Classification in Pharmacovigilance in the European Community (III/3445/95
– final)”. 
  

	6.)	Expedited ADE reporting 

 a) KREUSSLER shall report each
serious ADE through CIOMS form that occurred outside the TERRITORY as soon as possible but in no case later than 15 calendar days (expedited reporting) of initial receipt of the information to the LICENSEE. 
 b) The LICENSEE shall report each ADE that occurred in the TERRITORY and is both serious and unexpected as soon as possible but in no case later than 15
calendar days (expedited reporting) of initial receipt of the information to the competent TERRITORY REGULATORY AUTHORITY in a format as required by the TERRITORY. 
 This also applies to the use of an international acceptable medical dictionary if been made mandatory by TERRITORY regulations. 
 Unless otherwise defined by current TERRITORY-regulations the CIOMS form or FDA form 3500A should be used and filled out in English. This time frame must include a 3 working days review period of the report (in
English or as an English translation) by KREUSSLER. KREUSSLER’s comments shall be considered in the LICENSEE’s report. 

 The LICENSEE shall also submit follow up reports within 15 calendar days of receipt of new information or
as requested by the REGULATORY AUTHORITY. 
 Other circumstances for which reporting requirements exist according to current
TERRITORY-regulations shall be handled accordingly. 
 For documentation purposes KREUSSLER shall receive electronically by e-mail an English
CIOMS form (template will be provided by KREUSSLER) and copies of the last report sent to the authority electronically or by fax/mail. 
  

	7.)	Periodic ADE reporting 

 The LICENSEE shall report all ADEs
not described under Section 6.) to TERRITORY-health authority periodically (e.g. in form of a PSUR or Periodic Adverse Drug Experience Report) as defined by current TERRITORY regulations. 
  

	8.)	Information of serious expected and non serious ADEs 

 The
LICENSEE shall transmit serious expected ADEs by using the CIOMS form electronically within 15 calendar days to KREUSSLER by e-mail. 
 The
LICENSEE shall transmit non-serious ADEs by using the format of a CIOMS line listing (template will be provided by KREUSSLER) electronically within 15 calendar days to KREUSSLER by e-mail. 
  

	9.)	Case reports from the national literature 

 The LICENSEE
shall review the relevant medical literature in the TERRITORY at intervals in accordance with TERRITORY-regulations for published ADEs in connection with the preparations or the active ingredient(s) corresponding to the preparations and their use or
likely use. 
  

	10.)	National Pharmacovigilance regulations 

 The LICENSEE shall
provide to KREUSSLER copies (in English) of all relevant TERRITORY pharmacovigilance regulations (e. g. laws, directives, guidelines, etc.). Updates shall be processed accordingly. 
  

	11.)	Safety measures taken by the national authority 

 The
LICENSEE shall inform KREUSSLER immediately if the TERRITORY has taken safety measures directly in connection with the preparations or which could affect the preparations. 
  

	12.)	Support by KREUSSLER 

 KREUSSLER shall support the LICENSEE
with his scientific and regulatory knowledge to help the LICENSEE in fulfilling his pharmacovigilance responsibilities. 
  

	13.)	Annual ADE listings 

 KREUSSLER shall provide to the
LICENSEE an annual summary of all ADEs becoming known world-wide in connection with the preparation(s) by using CIOMS line listings within 1 month after the end of the concerning year for their information. 
  

	14.)	Changes to the safety evaluation of the preparations 

 In
case of any significant observations (e. g. higher incidence of known ADEs, new ADEs which should probably be listed (Company Core Safety Information)) regardless of the seriousness the LICENSEE and KREUSSLER shall discuss what, if any actions
should be taken. 

	15.)	Unforeseen safety problems 

 If unforeseen risks arise in
connection with the preparations (e. g. risks exceeding a single case), the LICENSEE’s Pharmacovigilance officer and KREUSSLER’s responsible persons shall discuss immediately the steps to be taken to protect the well-fare of patients and
the safety of the preparations. 
  

	16.)	Language 

 All documents described above must be provided
in English. 
  

											
	 BioForm Medical, Inc.
	 		 	Chemische Fabrik Kreussler & Co. GmbH
						
	 San Mateo, CA,
	 		 	Wiesbaden,	 		 		 	
						
	 /s/ Steven L. Basta
	 		 	 /s/ Dr. S. Travers
	 		 		 	 /s/ Dr. J. Otto

	 Steven L. Basta
 President and CEO
	 		 	 Dr. S. Travers
 Managing Director
	 		 		 	 Dr. J. Otto
 Director Med. Scientific
Dept.

 Appendix 1 to the Pharmacovigilance Agreement (Annex III) 
 Definition of preparations 
 Preparations for which this
contractual agreement apply to: 
  

							
	 Product
	  	 Composition
	  	 Presentation
	  	 Registration No.

	 Aethoxysklerol 0.5%
	  	(5 mg/ml polidocanol)	  	UNITS (i.e. [****])	  	
				
	 Aethoxysklerol 1%
	  	(10 mg/ml polidocanol)	  	UNITS (i.e. [****])	  	

  

									
	BioForm Medical, Inc.	 		 	Chemische Fabrik Kreussler & Co. GmbH
					
	San Mateo, CA,	 		 	Wiesbaden,	  		 	
					
	 /s/ Steven L. Basta
	 		 	 /s/ Dr. S. Travers
	  		 	 /s/ Dr. J. Otto

	 Steven L. Basta
 President and CEO
	 		 	 Dr. S. Travers
 Managing Director
	  		 	 Dr. J. Otto
 Director Med. Scientific
Dept.

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 Appendix 2 to the Pharmacovigilance Agreement (Annex III) 
 Currently relevant national pharmacovigilance regulations 
 The currently relevant pharmacovigilance regulations to be fulfilled by the LICENSEE are: 
  

	 	•	 	 CONTENT TO BE COMPLETED BEFORE APPROVAL OF THE FIRST PRODUCT 

  

	 	•	 	      

  

	 	•	 	      

  

	 	•	 	      

 and the
nominated pharmacovigilance officers are: 
  

	 	•	 	 CONTENT TO BE COMPLETED BEFORE APPROVAL OF THE FIRST PRODUCT  

  

	 	•	 	      

 Further revisions of these
regulations shall be followed independently by the LICENSEE in accordance with the other conditions of this agreement. 
  

									
	BioForm Medical, Inc.	 		  	Chemische Fabrik Kreussler & Co. GmbH
					
	San Mateo, CA,	 		  	Wiesbaden,	 		 	
					
	 /s/ Steven L. Basta
	 		  	 /s/ Dr. S. Travers
	 		 	 /s/ Dr. J. Otto

	 Steven L. Basta
 President and CEO
	 		  	 Dr. S. Travers
 Managing Director
	 		 	 Dr. J. Otto
 Director Med. Scientific
Dept.

 Appendix 3 to the Pharmacovigilance Agreement (Annex III) 
 KREUSSLER’s responsible person: 
 for pharmacovigilance pursuant to the
German law (“Stufenplanbeauftragter” für Medizinische Sicherheit) and KREUSSLER’s world-wide pharmacovigilance activities: 
 Dr. Joachim Otto 
 Tel: ++49/9271-126 
 Fax: ++49/9271-111 
 Mail: joachim.otto@KREUSSLER.de 
 Director Medical-Scientific Department, 
 Chemische Fabrik KREUSSLER & Co. GmbH 
 Rheingaustrasse 87-93, 
 D-65203 Wiesbaden, Germany. 
 or his deputy and responsible
person for the pharmacovigilance data management. 
 Dr. Wendelin Krause 
 Tel: ++49/9271-185 
 Fax: ++49/9271-111

 Mail: wendelin.krause@KREUSSLER.de 
 Chemische Fabrik KREUSSLER & Co. GmbH 
 Medical-Scientific Department, 
 Rheingaustrasse 87-93, 
 D-65203 Wiesbaden,
Germany. 
  

															
	BioForm Medical, Inc.	 		 	Chemische Fabrik Kreussler & Co. GmbH	 		 	
								
	San Mateo, CA,	 	 May 11, 2007
	 		 	Wiesbaden,	 	 May 11, 2007
	 		 		 	
		 	Date	 		 		 	Date	 		 		 	
						
	 /s/ Steven L. Basta
	 		 	 /s/ Dr. S. Travers
	 		 	 /s/ Dr. J. Otto
	 	
	Steven L. Basta	 		 	Dr. S. Travers	 		 	Dr. J. Otto	 	
	President and CEO of BioForm Medical	 	Managing Director	 		 	Director Med. Scientific Dept.	 	

 Annex IV to the Licensing and Distribution Agreement dated May 11, 2007 
 between BioForm Medical Inc. and Chemische Fabrik KREUSSLER & Co. GmbH 
 Product Specifications 
 CONTENT TO BE DISCUSSED, FINAL LIST UPON APPROVAL ACCORDING TO FINALLY APPROVED NDA

  

													
	 Chemische Fabrik
 Kreussler
& Co. GmbH
	 		  		  		  	 LICENSEE
 BioForm Medical,
Inc.

					
	 /s/ Dr. S. Travers
	 		  	 /s/ Dr. C. Freyberg
	  		  	 /s/ Steven L. Basta

	 Dr. S. Travers
 Managing
Director
	 		  	 Dr. C. Freyberg
 International
Marketing
 & Sales Director
 Pharmaceutical
Division
	  		  	 Steven L. Basta
 President
& CEO

							
	Wiesbaden,	 		 		  	 May 11, 2007
	  		  	San Mateo, CA	  	 May 11, 2007

		 		 		  	        Date	  		  		  	        Date

 Annex V to the Licensing and Distribution Agreement dated May 11, 2007 
 between BioForm Medical Inc. and Chemische Fabrik KREUSSLER & Co. GmbH 
 TRADEMARKS 
 AETHOXYSKLEROL(*) 
 [****] 
 [****] 
 ETOXISCLEROL(**) 
 ATOSSISCLEROL(**) 
 SCLEROVEIN(**) 
 VEINOSCLEROL(**) 
 EasyFoam(**) 
 [****] 

 Note:

	*	registered for KREUSSLER in the United States 

	**	filed by KREUSSLER for registration in the United States, registration pending. 

 [****] 
 KREUSSLER does not warrant that any trademark currently filed for registration in the United States and pending, or to be filed for
registration in the United States in the future, will actually be granted. 
  

													
	 Chemische Fabrik
 Kreussler
& Co. GmbH
	 		  		  		  	 BioForm
 BioForm Medical,
Inc.

					
	 /s/ Dr. S. Travers
	 		  	 /s/ Dr. C. Freyberg
	  		  	 /s/ Steven L. Basta

	 Dr. S. Travers
 Managing
Director
	 		  	 Dr. C. Freyberg
 International
Marketing
 & Sales Director
 Pharmaceutical
Division
	  		  	 Steven L. Basta
 President
& CEO

							
	Wiesbaden,	 		 		  	 May 11, 2007
	  		  	San Mateo, CA	  	 May 11, 2007

		 		 		  	        Date	  		  		  	        Date

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 Annex VI to the Licensing and Distribution Agreement dated May 11, 2007 
 between The LICENSEE Medical Inc. and Chemische Fabrik KREUSSLER & Co. GmbH 
 EASI Study TIMELINE*) 
  

					
	 	  	 [****]
	  	 [****]

	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]

	*)	Ref. Outline for Cooperation dated August 2006 

  

													
	 Chemische Fabrik
 Kreussler
& Co. GmbH
	 		  		  		  	 BioForm
 BioForm Medical,
Inc.

					
	 /s/ Dr. S. Travers
	 		  	 /s/ Dr. C. Freyberg
	  		  	 /s/ Steven L. Basta

	 Dr. S. Travers
 Managing
Director
	 		  	 Dr. C. Freyberg
 International
Marketing
 & Sales Director
 Pharmaceutical
Division
	  		  	 Steven L. Basta
 President
& CEO

							
	Wiesbaden,	 		 		  	 May 11, 2007
	  		  	San Mateo, CA	  	 May 11, 2007

		 		 		  	        Date	  		  		  	        Date

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.Exclusive Development, Distribution, and Supply Agreement dated October 27, 2006

 Exhibit 10.21 
 CONFIDENTIAL TREATMENT 
 EXCLUSIVE DEVELOPMENT, DISTRIBUTION, AND SUPPLY AGREEMENT 

This EXCLUSIVE DEVELOPMENT, DISTRIBUTION, AND SUPPLY AGREEMENT (the
“Agreement”) is entered into as of October 27th, 2006 (the “Effective Date”), by and between
(i) CryoLife, Inc., a Florida corporation, having a principal place of business at 1655 Roberts Blvd. NW, Kennesaw, Georgia 30144 (“Supplier”), and (ii) BioForm Medical, Inc., a Delaware corporation having a
principal place of business at 1875 South Grant Street, Suite 110, San Mateo, California 94402 (“BioForm”). 
 Background 
 WHEREAS, Supplier has developed and manufactures products based on serum albumin technology for use as a
surgical adhesive product. 
 WHEREAS, BioForm desires to develop, market, distribute, and sell adhesive products in the Territory (as
defined herein) for use in the Field as exclusive distributor for the Term (as defined herein); and 
 WHEREAS, Supplier desires to
appoint BioForm as exclusive distributor of Company Product in the Territory for use in the Field. 
 NOW, THEREFORE, in consideration
of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by each of the parties, Supplier and BioForm agree as follows: 
 1. DEFINITIONS 
 Capitalized terms used in this
Agreement and not otherwise defined herein shall have the respective meanings set forth below. 
 “Act” means the
United States Food, Drug and Cosmetic Act and similar laws and regulations in foreign jurisdictions within the Territory that regulate the manufacture, distribution, and sale of Company Product, all as may be amended from time to time. 

“Affiliate” means, with respect to any person, any person that, directly or indirectly, through one or more intermediaries,
controls, is controlled by, or is under common control with, such person. For the purposes of this definition, “control” means the direct or indirect ownership of more than 50 percent of the outstanding shares or other voting rights
entitled to vote for the election of directors (or in the case of an entity that is not a corporation, for the election of the corresponding management authority). Supplier shall not be deemed for any purposes of this Agreement to be an Affiliate of
BioForm. 
 “BioForm Trademarks” means all trademarks, other marks, and trade dress used by BioForm to identify
Company Product, any other product or service of BioForm, or the business identity of BioForm. 
 “BioGlue Surgical Adhesive” means Supplier’s BioGlue® surgical adhesive product described in the BSA Specifications and
that consists of a surgical adhesive composed of purified bovine serum albumin and glutaraldehyde. 
 “BSA Patents”
means (a) the Patent Rights identified on Exhibit A; (b) all non-provisionals, divisions, substitutions, continuations, and continuations-in-part applications of any of the Patent Rights identified on Exhibit A; (c) all patents
that may issue from any of the Patent Rights identified on Exhibit A; (d) any reissues and reexaminations of the Patent Rights identified on Exhibit A; and (e) all foreign and international counterparts of the Patent Rights identified on
Exhibit A. 
  

 “BSA Specifications” means the specifications for the BioGlue Surgical Adhesive
set forth on Exhibit B, as such specifications may be amended from time to time in accordance with the terms of this Agreement. 
 “Bulk Product Sample” means a unit of non-sterile Company Product provided unpouched in bulk quantities. 
 “Business Day” (whether such phrase is capitalized or not) means any day, other than Saturday, Sunday, or a legal holiday in California, that banks located in San Francisco, California are open
for business. 
 “Company Product” means a single syringe with 2 milliliters of deliverable volume (approximately 3
milliliters of fill volume) of BioGlue Surgical Adhesive with up to four applicator or spreader tips in a sterile pouch packaged in private label form specific to BioForm in a box provided by BioForm, which box may vary depending on the country to
which the Company Product will be shipped or other circumstances. Company Product includes Improvements that BioForm elects, with Supplier’s concurrence, to incorporate into Company Products pursuant to Section 8.4(a). 
 “Confidential Information” means all data, specifications, training materials, and other know-how related to the design, use,
implementation, performance, manufacture, distribution, or sale of BioGlue Surgical Adhesive or any Company Product, as well as all other information and data provided by either party to the other party hereunder in written or other tangible medium
and marked as confidential, or if disclosed orally or displayed, identified as confidential prior to or at the time of disclosure and confirmed in writing as confidential within 30 calendar days after disclosure, in each case except any portion
thereof that: (a) is rightfully known to the receiving party before receipt thereof under this Agreement as evidenced by the receiving party’s written records; (b) is properly and lawfully disclosed to the receiving party by a third
person who has the legal right to make such disclosure; (c) is or becomes generally lawfully known in the trade through no fault of the receiving party; or (d) is independently developed by the receiving party without use of such
information, as evidenced by the receiving party’s written records. 
 “Field” means sales to plastic surgeons,
facial plastic surgeons, ear, nose, and throat surgeons, occuloplastic surgeons and dermatologists for use in the following cosmetic and reconstructive procedures of the face, neck, and breast: (a) full-face lifts, mid-face lifts, brow lifts,
neck lifts, and other facial cosmetic facial reconstructive procedures; and (b) lifts, reductions, reconstructions, and augmentations of the breast. The Field may be expanded to include specific non-facial, non-breast surgical procedures
performed by plastic surgeons, facial plastic surgeons, ear, nose, and throat surgeons, occuloplastic surgeons, and dermatologists with the written consent of both parties. “FDA” means the United States Food and Drug
Administration, or any successor entity. 
 “Improvements” means developments, Enhancements, updates, and
other changes the Company Product or any component of the Company Product. 
 “Intellectual Property”
means intellectual property or proprietary rights of any description including: United States and foreign Patent Rights, trademarks, service marks, and registrations thereof and applications therefor, copyrights and copyright registrations and
applications, mask works and registrations thereof, know-how, trade secrets, inventions, discoveries, ideas, technology, data, information, processes, drawings, designs, licenses, computer programs and software, and technical information (including
information embodied in material specifications, processing instructions, equipment specifications, product specifications, confidential data, electronic files, research notebooks, invention disclosures, research and development reports and the like
related thereto), and all amendments, modifications, and improvements to any of the foregoing. 
  

 – 2 – 

 “Patent Rights” means all patents, patent applications (including
any provisionals, continuations, divisionals, continuations-in-part, extensions, renewals, reissues, revivals, and reexaminations, any national phase PCT applications, any PCT international applications, and all foreign counterparts) and rights to
file patent applications, any reissues or extensions thereof and any foreign counterparts, divisions, continuations, or continuation-in-part of any applications or substitutes therefor. 
 “Product Approvals” means, for any country or other jurisdiction in the Territory, those regulatory approvals required for
importation, exportation, promotion, pricing, marketing, and sale of the Company Product in such country or other jurisdiction for use in the Field. 
 “Product Specifications” means the specifications for the Company Product as they are agreed to in writing from time to time in accordance with the terms of this Agreement.

 “Proprietary Rights” means Intellectual Property licensed to, owned or controlled by Supplier that
is used in the design, formulation, manufacturing or packaging of the Company Product. 
 “Regulatory Authority”
means the FDA and any other national, supra-national, regional, state, or local regulatory agency, department, bureau, commission, council, or other governmental entity empowered by any Act to regulate the Company Product (including the manufacture,
distribution, or sale of the Company Product) within the Territory. 
 “SA Product” means any surgical adhesive
capable of being used in the Field that is composed of serum albumin combined with any aldehyde or whose design or formulation is covered by any claim of the BSA Patents. 
 “Supplier Trademarks” means the BioGlue trademark and all other marks and trade dress used by Supplier to identify the BioGlue Surgical Adhesive or the business identity of
Supplier. Supplier Trademarks include, without limitation, those marks and trade dress identified on Exhibit D. 
 “Territory” means the United States, Canada, and each European country, territory, and possession that is specified on Exhibit C and is subject to and governed by the CE medical products rules under European
Union Medical Device Directive 93/42/EEC. The Territory may be expanded to include other countries, territories, or possessions that subsequently become subject to and governed by the CE medical products rules under European Union Medical Device
Directive 93/42/EEC with the written consent of both parties. The European countries, territories, and possessions specified on Exhibit C are sometimes collectively referred to as the “EC Countries.” 
 “Training Product Sample” means a unit of Company Product provided that is marked “Not for Commercial Sale” in a
manner agreed upon by the parties. 
 Other Defined Terms. Each of the following terms shall have the respective
meaning ascribed to such term in the section of this Agreement set forth opposite such term below: 
  

			
	 	  	 Section

	 “Agreement”
	  	Preamble
	 “CGMP”
	  	6.1
	 “Blocking Intellectual Property”
	  	8.4(c)
	 “Regulatory Approval Program”
	  	3.1
	 “Regulatory Approval Plan”
	  	3.1
	 “Complaint“
	  	6.8(a)
	 “Complaint Evaluation“
	  	6.8(b)

  

 – 3 – 

			
	 	  	 Section

	 “Development Agreement”
	  	8.4(b)
	 “Development Effort Data” 
	  	11.3
	 “Effective Date“
	  	Preamble
	 “Enhancements”
	  	8.4(a)
	 “Enhancements Notice”
	  	8.4(a)
	 “Indemnifying Party“
	  	10.2
	 “Indemnitees“
	  	10.2
	 “Losses“
	  	10.1(a)
	 “Prior Forecast”
	  	5.3(b)
	 “Process Complaint”
	  	6.8(c)
	 “Process Related Recalls”
	  	6.10(b)
	 “Product Development Meeting”
	  	8.4(a)
	 “Product Information”
	  	8.1
	 “Program”
	  	8.4(b)
	 “QSR”
	  	6.1
	 “Supplier“
	  	Preamble
	 “Term“
	  	11.1
	 “Transfer Price”
	  	5.12(a)

 2. LICENSE GRANT & PAYMENT 
 2.1 License Grant. Supplier hereby grants to BioForm an exclusive license under the BSA Patents and Proprietary Rights solely to develop, in
cooperation with Supplier, and to use, distribute, market, and sell, but not to make or manufacture, Company Product within the Field in the Territory. BioForm may sublicense rights to use, distribute, market, and sell under the license grant to
Affiliates who agree to be bound by the license and distribution limitations contained in this Agreement. 
 2.2 Considerations. As
compensation for the license grant contained in Section 2.1, BioForm shall (a) pay Supplier a one-time payment of $500,000 upon the execution of this Agreement, (b) pay Supplier any and all milestone payments coming due under
Section 3.3, and (c) purchase Company Product exclusively from Supplier in the manner provided herein. 
 3. DEVELOPMENT AND REGULATORY
APPROVALS 
 3.1 Development in the Field by BioForm. BioForm will use reasonable efforts to promptly design, fund, and conduct a
program intended to gain required Regulatory Approvals to market and sell Company Product in the United States, Canada, and the EC Countries for at least one indication within the Field, such as endoscopic brow lifts, that is reasonably acceptable
to Supplier, which acceptance will be communicated prior to the initiation of the program and will not be unreasonably withheld or delayed (the “Regulatory Approval Program”). BioForm will use reasonable efforts to execute
the Regulatory Approval Program in accordance with the Regulatory Approval Program, as such program may be amended from time to time. In connection with such clinical development activities: 
 (a) BioForm will bear all costs of the Regulatory Approval Program, including the cost of regulatory submissions, clinical trials, and activities to
support approval by the applicable Regulatory Authority in the United States, Canada, and the EC Countries except that BioForm shall not be required to reimburse Supplier for any costs or expenses incurred by it or its Affiliates, contractors, or
agents in connection with the non-financial assistance and cooperation that are provided free of charge under Section 3.2(b) and 3.2(c). BioForm will be responsible for the preparation of regulatory documents and submissions to the FDA in
connection with the Regulatory Approval Program. 
  

 – 4 – 

 (b) BioForm will develop a reasonably detailed written project timeline with milestones and resource
commitments for the Regulatory Approval Program (the “Regulatory Approval Plan”) that is reasonably acceptable to Supplier, which acceptance will not be unreasonably withheld or delayed, within 60 days after execution of this
Agreement. The Regulatory Approval Plan will establish: (i) the scope and time frame of the development activities that will be performed, (ii) development objectives, work plan activities, and time schedules with respect to the Regulatory
Approval Program, (iii) the obligations of the parties with respect to the Regulatory Approval Program, (iv) a budget for the various activities to be performed, and (v) a non-binding estimate of quantities of Company Product supply
needed for use as part of the Regulatory Approval Program. Attached as Exhibit 3.1(b) is a preliminary Regulatory Approval Plan developed by BioForm that will be superseded by the Regulatory Approval Plan but will serve as BioForm’s acting
Regulatory Approval Plan until the final Regulatory Approval Plan is completed and accepted by Supplier in the manner provided above, and such approval shall not to be unreasonably withheld, conditioned or delayed. Supplier agrees to accept any
Regulatory Approval Plan that is consistent with the preliminary Regulatory Approval Plan, provides for at least the same level of financial and resource commitment from BioForm as the preliminary Regulatory Approval Plan, and maintains, subject to
delays beyond the control of BioForm, substantially the same timeline as the preliminary Regulatory Approval Plan. 
 (c) Supplier shall
supply BioForm, at Supplier’s cost, a reasonable amount of Company Product for the Regulatory Approval Program, as contemplated by the Regulatory Approval Plan. 
 3.2 Regulatory Approvals. BioForm shall be responsible, at its expense, for obtaining, maintaining, and complying with all regulatory requirements, excluding requirements for manufacturing, and approvals
(including all Product Approvals) necessary or useful to market and sell Company Product in the Field within any jurisdiction of the Territory in which BioForm will market or sell Company Product. All regulatory approvals shall be obtained in the
name of and owned by BioForm. In pursuing such approvals: 
 (a) BioForm shall permit Supplier to review and comment upon BioForm’s
regulatory and clinical trial plans for the Territory. BioForm shall also be responsible for making all applicable regulatory filings. 
 (b)
Supplier will provide BioForm with non-financial assistance and cooperation in support of the Regulatory Approval Program, as reasonably requested by BioForm. Such assistance will include reasonable consultation with Supplier’s employees,
consultants, and agents on technical and regulatory matters, including acting as the sponsor of any potential premarket application supplements or other regulatory filings, and providing access to relevant historical research, development, clinical,
and regulatory files necessary for implementation of the Regulatory Approval Program and the submission of related premarket applications. 
 (c) Supplier shall permit BioForm to use any data owned by Supplier to support each premarket or regulatory application being made by BioForm for Company Product in the Field in the Territory. Supplier shall also permit BioForm to reference
such data in submissions to each Regulatory Authority and permit the Regulatory Authority to use such data in its reviews. Supplier shall update the data submissions it makes under this Section 3.2 and provide BioForm with all new data promptly
after the same is developed, assembled, or comes to the attention of Supplier. BioForm will provide the same rights and privileges to Supplier with respect to data owned or generated by or on behalf of BioForm in connection with the Company Product.
Information provided by either party pursuant to this Section 3.2(c) is subject to the confidentiality provision in Section 12.7. 
 (d) During the period beginning on the Effective Date and ending upon completion of the Regulatory Approval Program, at Supplier’s request, BioForm will provide Supplier with a reasonably detailed written report summarizing the
progress of the Regulatory Approval Program once each calendar 
  

 – 5 – 

 
quarter and, at Supplier’s request, meet with representatives of Supplier in person or by phone no more frequently than once per calendar quarter to
discuss progress with the Regulatory Approval Program. BioForm shall review with Supplier clinical trial protocols and the selection of clinical sites of any clinical trial to be conducted with respect to Company Product. BioForm will own all data
generated by or for BioForm or its Affiliates in the Regulatory Approval Program, except for data generated by Supplier, which data Supplier shall own. 
 (e) Supplier shall provide to BioForm, at Supplier’s expense, copies of its existing scientific, medical, clinical, regulatory technical, marketing, and other data related to the BioGlue product to support
BioForm’s clinical, regulatory, or marketing activities. BioForm shall provide to Supplier, at BioForm’s expense, summaries of its scientific, medical, clinical, regulatory technical, marketing, and other data related to the Company
Product to support Supplier clinical, regulatory, or marketing activities related to BioGlue Surgical Adhesive. 
 (f) BioForm will not be
liable for any costs associated with Supplier’s efforts in connection to maintaining and complying with all applicable regulatory requirements in the ordinary course of business for any product (including the BioGlue Surgical Adhesive or
Company Product). 
 3.3 Approval Milestone. BioForm shall pay to Supplier a milestone payment equal to [****] upon BioForm receiving
the first PMA approval from the FDA to market and sell the Company Product in any application within the Field in the United States. 
 4. DISTRIBUTION
AND PURCHASE 
 4.1 Appointment. Subject to the terms and conditions set forth in this Agreement, Supplier hereby appoints BioForm
as Supplier’s exclusive distributor of Company Product in the Field within the Territory for the Term, and BioForm hereby accepts such appointment. BioForm may appoint Affiliates as sub-distributors, but only those Affiliates to whom they have
granted sublicense rights under Section 2.1. Supplier acknowledges and agrees that it shall not be entitled to any compensation for the appointment contained in this Section 4.1 other than payment of the purchase price for Company Product
in accordance with Section 5.6 and payments due under Section 3.3. 
 4.2 Distribution Relationship; Limitations on Supplier
Activities. During the term of this Agreement, Supplier agrees to sell Company Product for use in the Field within the Territory exclusively to BioForm. Subject to the last sentence of this Section 4.2, Supplier agrees (a) not to
provide or sell any SA Product in the Field in the Territory for or to any third party if Supplier knows or has reason to believe that such SA Product will be provided, distributed, or sold anywhere in the Territory for use in the Field; and
(b) to use its commercially reasonable efforts to prevent the sale of any SA Product to customers for resale or distribution in the Field within the Territory by any party other than BioForm or its Affiliates, including commercially reasonable
efforts requested by BioForm, to prevent such unauthorized sales activity. The foregoing provisions of this Section 4.2 shall not be deemed to prohibit Supplier from developing or commercializing any SA Products (including the BioGlue Surgical
Adhesive) or any other product for any application outside the Field (whether inside or outside the Territory) or outside the Territory (whether or not within the Field). Supplier shall not be obligated under this Section 4.2 from and after
such time, if ever, as BioForm is in breach of its obligations under Section 4.5 and has not cured such breach within 60 days of written notice from Supplier notifying BioForm of such breach. 
 4.3 No Other Distributors. Supplier represents and warrants that, except to the limited extent disclosed on Exhibit 4.3, it does not currently
have any other agents, representatives, or distributors entitled to market, sell, or distribute SA Product in the Field within the Territory. Supplier represents and warrants that, except to the limited extent disclosed on Exhibit 4.3, there is no
restriction, covenant, or agreement to which it 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 6 – 

 
is a party or by which it is bound that would prevent or delay Supplier from providing to BioForm the exclusive distribution rights contained in this
Agreement, and Supplier agrees that it will not, directly or indirectly, undertake any action, omit to take any action, or enter into any agreement that will prevent or delay BioForm from the enjoyment by BioForm of the full benefits of exclusive
distribution relationship provided in this Agreement. Supplier will 4.4 use commercially reasonable efforts to amend the agreement disclosed on Exhibit 4.3 of any distributor that markets SA Product into the Field so as to prohibit the distributor
from distributing SA Product in the Field in the Territory during the term of this Agreement; and 4.5 terminate, or allow to expire, each agreement disclosed on Exhibit 4.3 in accordance with its terms if the agreement cannot be amended to prohibit
the third party from distributing SA Product in the Field in the Territory during the term of this Agreement. BioForm agrees not to contact any party to an agreement disclosed in Exhibit 4.3 without the prior written consent of Supplier. Supplier
will use its reasonable best efforts to complete the efforts required of Supplier by this Section 4.3 before the earlier of BioForm receiving PMA Approval to distribute Company Product in the United States or BioForm commencing active
distribution and promotion of Company Product in Canada or the EC Countries. 
 4.4 Marketing and Sales. All business decisions
concerning the sales and marketing of Company Product for use in the Field in the Territory, including the price, other sale terms, kitting practices, and promotion thereof, will be within the sole discretion of BioForm. Upon Supplier’s
reasonable request, but no more frequently than twice per calendar year, BioForm will discuss with Supplier BioForm’s marketing plans for Company Product in the Territory. Within 30 calendar days following the end of each calendar quarter,
BioForm will also provide Supplier with a written report of the following items during the prior calendar quarter in each of the United States, Canada, and the EC Countries (a) the volume of all sales of Company Product, (b) the total
revenue for all sales of Company Product, and (c) the average selling price of Company Product. BioForm will provide Supplier with an annual evaluation of the current and expected market situations with respect to Company Product in the
Territory in the Field. This evaluation will be provided to Supplier in January of each calendar year of this Agreement. 
 4.5 Limitation
on Activities of BioForm. Throughout the term of this Agreement, BioForm agrees (a) to offer for sale Company Product only for use in the Field within the Territory; (b) not to provide or sell any Company Product to any third party
that will provide, distribute, or sell the Company Product anywhere outside the Territory or for use outside the Field if BioForm knows or has reason to believe that such Company Product will be provided, distributed, or sold anywhere in the outside
Territory or for any use outside the Field; and (c) to use commercially reasonable efforts to prevent the resale or distribution of any Company Product to customers for resale or distribution outside the Field or the Territory by any party,
including commercially reasonable efforts requested by Supplier, to prevent such unauthorized sales activity. 
 4.6 Commercially
Reasonable Sales Efforts. Notwithstanding the terms of Section 4.4, BioForm shall use commercially reasonable efforts, consistent with its ordinary course of conduct, to commercialize, market, and sell Company Product for use in the Field
in the Territory during the term of this Agreement so long as Supplier supplies Company Product to BioForm in accordance with the terms of this Agreement provided that (a) BioForm shall not be required to use any level of efforts to sell,
market, or distribute Company Product in any jurisdiction prior to receipt of all Product Approvals reasonably deemed by BioForm to be necessary for the marketing and sale of Company Product in such jurisdiction; and (b) whether certain efforts
by BioForm are deemed to be “commercially reasonable” with respect to Company Product shall be determined in light of all relevant factors in the relevant jurisdictions including (i) BioForm’s reasonable estimate of the market
potential and rate of market growth of Company Product (including anticipated profit margin and the perceived market size); (ii) the level of Product Approval for Company Product in each jurisdiction (including the extent of the indications, if
any, within the Field for which Company Product has been approved); (iii) in BioForm’s reasonable estimation, whether or not the sale of Company Product infringes or could infringe the Patent Rights of third persons in the Territory;
(iv) the competitive position of Company Product vis-à-vis other products that may be marketed and sold for the same indications, including 

  

 – 7 – 

 
with respect to the safety, efficacy, and cost of Company Product when compared to such other products; and (v) the availability and supply of Company
Product for distribution. BioForm’s reasonable commercial efforts may include one or more of the following (1) promoting Company Product at major medical trade shows attended by plastic surgeons, facial plastic surgeons, ENT surgeons,
occuloplastic surgeons and dermatologists, (2) training, educating, supporting and maintaining representatives to market and sell Company Product in the Territory within the Field, or (3) applying reasonable financial, personnel and
facilities resources in support of its commercialization efforts. For purposes of determining whether or not BioForm is complying with its obligations under this Section 4.6, BioForm’s sales and marketing efforts for Company Product in all
relevant jurisdictions within the Territory shall be considered in the aggregate, and not by separate jurisdiction. 
 4.7 Marketing
Costs. Except as otherwise expressly provided in this Agreement, BioForm shall bear all expenses for marketing and selling Company Product in the Field in the Territory. 
 4.8 Product Differentiation. In order to appropriately distinguish Company Product sold by BioForm from BioGlue Surgical Adhesive sold by
Supplier, BioForm will (a) market and distribute Company Product exclusively under a new and separate brand and name approved in advance by Supplier, which approval shall not be unreasonably withheld or delayed, and (b) refrain from
actively marketing any connection between the Company Product and the BioGlue Surgical Adhesive. BioForm may make references to the safety of the BioGlue Surgical Adhesive in response to inquiries but not in any marketing communications or
materials. The provisions of this Section 4.8 shall not apply to activities performed by BioForm in connection with conducting clinical trials or regulatory filings as outlined in the Regulatory Approval Program or Regulatory Approval Plan in
accordance with Section 3.2. For purposes of clarification, responding to questions regarding commonalities between the BioGlue Surgical Adhesive and the Company Product will not be considered “active marketing” that violates
Section 4.8(b). Notwithstanding the foregoing, the parties will enter into good faith negotiations regarding an alternate brand and name strategy for the Company Product, including the possibility of incorporating the BioGlue brand, name and
trademark or derivations thereof into the brand and name for the Company Product. 
 4.9 Right of First Negotiation. Supplier agrees
to consider BioForm as a potential exclusive distributor in the Territory of any SA Product it desires to distribute within the Field. This undertaking shall require Supplier to first disclose the potential SA Product to BioForm in writing prior to
disclosure to other parties. If BioForm notifies Supplier in writing that it desires to negotiate for exclusive distribution rights within the Field and Territory for the disclosed SA Product within [****] after notice to BioForm of the availability
of such SA Product, Supplier shall enter into good faith negotiations with BioForm to determine commercially reasonable terms for such rights. Such discussions shall be exclusive for a period of [****]. Potential SA Product information disclosed
pursuant to this Section 4.9 shall be considered Supplier Confidential Information under Section 12.7. 
 5. PURCHASE OF PRODUCTS AND TERMS OF
SALE 
 5.1 Exclusive Purchase and Supply Relationship. BioForm agrees to purchase Company Product exclusively from Supplier in
accordance with the terms of this Agreement for so long as Supplier supplies the Company Product in accordance with the terms of this Agreement. 
 5.2 Forecasts. BioForm agrees to provide Supplier, to the extent practicable, at least six months prior to the date of anticipated first commercial release of any Company Product and at least 30 calendar days prior to the beginning
of each calendar quarter, a 12-month rolling forecast (limited to months during the Term) of its intended Company Product purchases. Except as set forth in Section 5.3(a), all forecast information shall be for informational purposes only and
shall not be a commitment to purchase. All forecasted amounts are for delivery of Company Product at the beginning of the month for which the forecast is made. 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 8 – 

 5.3 Purchase Orders. BioForm shall submit to Supplier purchase orders for Company Product that
shall, at a minimum, identify the Company Product and set forth the quantities, price, delivery dates, and shipping instructions and shipping addresses for the Company Product ordered. Minimum purchase quantity shall be five units of Company
Product. 
 (a) Firm Commitments. With each rolling forecast submitted to Supplier, BioForm shall submit binding purchase orders to
cover [****] of the Product orders included in the forecast for the initial three-month period of such forecast. Further, BioForm commits to purchase at least [****] of the Company Product orders forecast for the immediately subsequent three month
period of each rolling forecast submitted to Supplier. Company Product orders forecast for the remaining period of the forecast shall be non-binding. 
 (b) Purchase Order Acceptance. Each purchase order shall be deemed to have been accepted by Supplier, upon receipt in a manner that provides proof of delivery, if the order quantity for that quarter is within
[****] of the amount of Company Product set forth for that quarter in the forecast submitted by BioForm to Supplier before the beginning of the immediately prior quarter (the “Prior Forecast”) and within the agreed-upon lead-time for such
Company Product. Each accepted purchase order shall give rise to a contract between BioForm and Supplier for the sale of the Company Product units ordered and shall be subject to and governed by the terms of this Agreement. The terms and conditions
of this Agreement shall govern and supersede any additional or contrary terms set forth in BioForm’s purchase order or any Supplier or BioForm acceptance, confirmation, invoice, or other document unless duly signed by an officer or designee of
both BioForm and Supplier expressly stating and identifying which specific additional or contrary terms shall supersede the terms and conditions of this Agreement. 
 (c) Order Limitations. The amount of the initial purchase order and initial forecast for Company Product shall be agreed to by BioForm and Supplier. Later forecasts shall require Supplier’s agreement only
if they increase Company Product forecasts for any quarter by more than [****] of the amount forecasted in the Prior Forecast. In the event the purchase orders placed by BioForm for delivery within any quarter is greater than [****] of the amount of
Company Product set forth in the Prior Forecast, Supplier shall not be obligated to supply any such excess above [****] however, Supplier shall use its commercially reasonable efforts to supply such excess. 
 5.4 Product Specifications; Packaging and Labeling. All Company Product delivered by Supplier hereunder shall be in full compliance with Product
Specifications, shall be labeled specifically for BioForm, and shall be ready for end-user sale, including all packaging, labeling, instructions-for-use, and sterilization, as approved by BioForm. BioForm will develop and implement packaging and
labeling for Company Product, subject to applicable regulatory requirements and consent of Supplier, which consent shall not be unreasonably withheld or delayed, to clearly differentiate Company Product from BioGlue Surgical Adhesive products sold
by Supplier. Supplier shall ensure that all Company Product shall be labeled in accordance with the procedures specified from time to time by BioForm and BioForm shall have final approval over all packaging and labeling for Company Product, except
for the consent provided for in the immediately preceding sentence. BioForm maintains the right to over-label Company Product as it deems necessary, but shall not utilize Supplier Trademarks except in accordance with Section 7.1, and
shall provide Supplier with copies of any additional labels used by BioForm. 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 9 – 

 5.5 Obligation to Stock and Supply 
 (a) Supplier shall manufacture, sell, and deliver Company Product to BioForm and BioForm shall purchase Company Product from Supplier in accordance with
this Agreement and the related purchase orders on the date specified for delivery in the purchase order (which date shall not be earlier than 30 calendar days after the date of the purchase order). 
 (b) Supplier will use its reasonable best efforts to maintain the ability to supply all Company Products that Supplier is required to deliver pursuant to
Section 5.2. If Supplier becomes or projects that it may be incapable of making such required deliveries of Company Products, subject to normal lead-time requirements, Supplier agrees to meet with BioForm and agree to a reasonable allocation
plan to assure BioForm a fair allocation of Supplier resources to meet BioForm’s requirements for Company Product. Supplier will provide BioForm with as much notice as reasonably possible if it anticipates or has reason to believe that
Supplier’s output of the Company Product will not be sufficient to supply all Company Products that Supplier is required to deliver pursuant to Section 5.2 and 5.3. 
 (c) Supplier shall maintain at all times a supply of raw material inventory necessary to manufacture Company Product for three months as forecasted to be
purchased by BioForm based on the most recent forecast. In addition, Supplier shall maintain at all times manufacturing capacity and raw materials sufficient to supply at least [****] estimated quantity of purchase for the first six months of the
most recent forecast. 
 (d) BioForm shall maintain at all times a supply of Company Product finished inventory equal to approximately [****]
supply. 
 5.6 Payment. Supplier shall invoice BioForm for Company Product delivered to BioForm in accordance with this Agreement and
purchase orders at the prices described in Section 5.12. BioForm shall pay for Company Product within 40 calendar days after the date of Supplier’s invoice (provided that the invoice date is no earlier than the date that shipment is
received), unless BioForm has not accepted the delivery in accordance with Section 5.9. Late payments shall bear interest at the prime rate per annum. In the event that Supplier is required to institute any action to enforce collection of any
amounts due to Supplier from BioForm under this Agreement, BioForm shall pay, in addition to all amounts due, all reasonable out-of-pocket costs and expenses incurred by Supplier in connection with the collection of such amounts, including
reasonable attorneys’ fees and disbursements. 
 5.7 Samples 
 (a) Upon BioForm’s request, Supplier will sell to BioForm Bulk Product Sample units for use by BioForm only as samples used in sales demonstrations
and trade shows and for regulatory purposes but not in surgical procedures involving humans. The number of Bulk Product Sample units to be sold to BioForm under this Section 5.7 during any calendar quarter shall not exceed [****] of the
aggregate number of product units ordered by BioForm during the immediately prior calendar quarter. Notwithstanding the foregoing, Supplier shall sell to BioForm [****] Bulk Product Sample units for the EC Countries and [****] Bulk Product Sample
units for the United States, respectively, in the first six months following the commercial launch of Company Product in such regions. The price for each Bulk Product Sample unit will equal [****] per unit. 
 (b) Upon FDA PMA approval and upon BioForm’s request, Supplier will sell to BioForm Training Product Samples at [****] per Training Product Sample
unit for use by BioForm only as samples in the Territory. Training Product Samples may be used in sales demonstrations and trade shows, for regulatory purposes, for clinical in-service training, and for demonstration on humans so long as there is no
charge for such use by BioForm. Supplier shall sell Training Product Sample units to BioForm for use as follows: (i) up to [****] Training Product Sample units following the commercial launch of Company Product 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 10 – 

 in the United States and (ii) up to [****] Training Product Sample units during each quarter for the seven quarters
following FDA PMA approval. 
 (c) BioForm may not sell any Bulk Product Sample units or Training Product Samples. If requested by Supplier,
BioForm shall certify in writing that sample product units were used only in compliance with this Section 5.7. 
 5.8 Delivery
Terms. All deliveries of Products shall be F.O.B. Supplier’s manufacturing facility. Supplier shall have no further responsibility for Products after, and all risk of damage to or loss or delay of Products shall pass to BioForm upon,
delivery by Supplier at the F.O.B. location to the common carrier specified by BioForm or, in the event that no carrier shall have been specified by BioForm on or before the date 15 days prior to the requested shipment date, a common carrier
reasonably selected by Supplier, or in the event that BioForm delays shipment more than four business days following the delivery date stated in the applicable purchase order. BioForm shall be responsible for all shipping, handling, insurance, and
inventory holding (from the third business day following such delivery) costs resulting from Product deliveries in accordance with this Section 5.8. BioForm agrees to store, transport, and deliver Company Product in a manner that ensures
Company Product is delivered to the end user in good condition. Supplier shall deliver all Company Products to BioForm free and clear of all liens and encumbrances or other defects in title. 
 5.9 Acceptance 
 (a) Each shipment of
Company Product from Supplier to BioForm shall contain such quality control certificates reasonably requested by BioForm certifying that the Company Product units shipped conform to the Product Specifications. Notwithstanding any prior inspection or
payments, all Company Product will be subject to final inspection and acceptance at BioForm’s designated destination point within fifteen business days after delivery. BioForm shall notify Supplier within fifteen business days after delivery of
any apparent defective material or workmanship or non-conformity of any Company Product unit to the Product Specifications, purchase order, or, if apparent, the requirements of Section 6.1. If BioForm fails to so notify Supplier, BioForm will
be deemed to have accepted the Company Product units received; provided, that the warranty set forth in Section 9.2 shall survive acceptance of the Company Product by BioForm. 
 (b) Without prejudice to any other right or remedy of BioForm, in case any item is defective in material or workmanship, or otherwise not in conformity
with the Product Specifications, the requirements of BioForm’s purchase order, or the requirements of Section 6.1, BioForm will have the right to reject it. Any item that has been rejected must be replaced by and at the expense of Supplier
promptly after notice. BioForm will not be required to pay for any rejected item, or its shipping costs or any other costs related thereto. BioForm will return all rejected Company Product to Supplier at Supplier’s expense. Supplier shall
investigate the cause for the rejection and provide to BioForm in writing all proposed corrective actions associated with the cause for rejection. 
 5.10 Changes. Supplier shall not make any changes to Company Product (including materials, packaging, and directions for use), the BSA Specifications, the Product Specifications, raw materials, component suppliers, or manufacturing
process for Company Product, which in any case could reasonably be expected to affect the form, fit, function, regulatory status, or efficacy of the Company Product or patient safety, unless approved by BioForm in writing in advance, which approval
may not be unreasonably denied. Without limiting the foregoing, all such changes (including changes required by law) shall be submitted to BioForm no later than 60 calendar days prior to Supplier’s proposed date of implementation for such
change. Unless BioForm notifies Supplier in writing that it disapproves of such change during the 60-calendar day period or if such a proposed change is otherwise required by law, regulation, or Regulatory Authority directive, Supplier shall be
authorized to implement such change and shall be responsible for properly 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 11 – 

 
communicating and implementing such change, including with respect to any of Supplier’s vendors. Without limiting the foregoing, the following changes
shall be deemed governed by this Section 5.10: (a) use of any nonconforming material in the manufacture of any Company Product in variance with the Product Specifications; (b) implementation of any Supplier-authorized temporary
deviation that could affect the handling, sterility, safety, or efficacy of any Company Product and be at variance with the Product Specifications; or (c) implementation of any Supplier-initiated corrective action that could affect the safety
or efficacy of the Company Product. The foregoing is not intended to limit Supplier’s ability to make changes to any product other than the Company Product (or any of its components). 
 5.11 Supply Interruption Notice. Supplier will notify BioForm immediately in writing upon becoming aware of any material obsolescence, supply
shortage, or other interruption or potential interruption in the supply of any material, component, or sub-assembly, in each case as it relates to Company Product. 
 5.12 Transfer Price 
 (a) Company Product Price. Except as otherwise provided for the purchase
of samples in Section 5.7 and subject to the terms of this Section 5.12, BioForm shall pay Supplier a transfer price (the “Transfer Price”) for any Company Product delivered to and not rejected by BioForm equal to
(i) until BioForm has ordered and accepted [****] units of Company Product in any calendar year, [****] per product unit; (ii) thereafter, until BioForm has ordered and accepted [****] units of Company Product in any calendar year, [****]
per product unit; and (iii) thereafter, for any remaining units of Company Product ordered and accepted in any calendar year, [****] per unit. 
 (b) Component Price. From time to time, BioForm may request to individually purchase components, such as applicator tips, of the Company Product for use in connection with the sale of Company Product. BioForm shall pay Supplier a
transfer price for any component in an amount to be negotiated in good faith between the parties. 
 (c) Adjustments to Transfer
Price. Additionally, the parties agree to use commercially reasonable, good faith efforts to negotiate adjustments to the Transfer Price if (a) requested by Supplier, and only if Supplier’s cost to manufacture Company Product [****]
since the Effective Date or latest prior price adjustment; or (b) requested by BioForm, upon the occurrence of a change in market dynamics that results in BioForm [****] since the Effective Date or latest prior price adjustment. 
 (d) No Limitation on Pricing. Nothing contained herein shall be deemed to limit in any way the right of BioForm to determine the prices at which,
or the terms on which, Company Product purchased by BioForm may be resold by BioForm. Supplier will be responsible for any royalties or fees payable by Supplier or BioForm to any third party with respect to any agreement concerning such third
party’s Intellectual Property or other proprietary rights associated with the import, export, use, sale, or distribution hereunder of any Company Product. 
 6. COMPLIANCE 
 6.1 Manufacturing Requirements. Supplier will manufacture Company Product in accordance with the
then-current (a) Product Specifications, (b) applicable regulations relating to current Good Manufacturing Practices and similar protocols required by the Act (“CGMP”), quality system regulations of the FDA
(“QSR”), including master device and lot history records, and ISO 13485 requirements (including appropriate certification), MDD requirements, CMDCAS requirements, and (c) other pertinent rules and regulations of
Regulatory Authorities that have approved sale of the Company Product. Upon the request of BioForm, Supplier shall provide BioForm with written evidence of compliance with the criteria set forth in the preceding sentence. During the Term, Supplier
will maintain, or cause to be maintained, the Company 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 12 – 

 
Product manufacturing facility’s registration as a certified medical device manufacturing facility with all applicable Regulatory Authorities or cause
such facility to be maintained such that the facility would pass an audit for compliance with CGMP and QSR. Supplier shall maintain ongoing quality assurance and testing policies sufficient to satisfy its obligations under this Agreement,
BioForm’s standard requirements for approval as a vendor as described in BioForm’s supplier quality system review policy, and Supplier’s standard quality assurance policies, copies of which are attached hereto. For seven years after
delivery to BioForm of each Company Product unit, or such longer period as may be required by CGMP and other applicable rules and regulations of any Regulatory Authority, Supplier shall (i) maintain traceability for each Company Product unit
including the manufacturing date and lot number of each Company Product unit and each component and material comprising each Company Product and (ii) provide BioForm a copy of such records upon BioForm’s written request. 
 6.2 Regulatory Communications. Each party shall promptly notify the other and provide to the other a copy or transcription, if available, of any
communication from any Regulatory Authority relating to Company Product, the marketing thereof, or any related matter (including copies of all Product Approvals) and shall keep the other party reasonably apprised of regulatory interactions and
similar activities with governmental authorities and international bodies in connection with Company Product anywhere in the Territory. 
 6.3 Traceability Program. BioForm shall be responsible for maintaining medical device vigilance systems in the Territory as required by laws applicable to distributors of products such as the Company Product, and shall provide
Supplier with reasonable access to such records. 
 6.4 Notices. Each party shall notify the other immediately by fax, with confirming
notice via overnight delivery, as soon as it becomes aware of any issue with Company Product or its testing, manufacture, labeling, or packaging, occurring within the Territory or outside of the Territory, including any issue relating to regulatory
compliance, safety or efficacy of Company Product or breach by the party of the terms of this Agreement. Without limiting the generality of the foregoing, each party will notify the other immediately if it becomes aware of any death or bodily injury
caused by a Company Product unit (or suspected to be caused by a Company Product unit) or any malfunction of Company Product occurring within the Territory or outside of the Territory or any regulatory or ISO inspections or other communications with
regulatory or ISO authorities related to the Company Product or that would in any way impact Company Product or the party’s performance of its responsibilities hereunder. 
 6.5 Compliance with Laws. Each party will comply with all laws and regulations in the Territory applicable to it that pertain to the testing,
manufacture, labeling, marketing, distribution, sale, or packaging of Company Product and in any other manner pertaining to the performance of its obligations under this Agreement, including the maintenance of ongoing quality assurance and testing
procedures to comply with applicable regulatory requirements. Each party will also comply with all laws and regulations applicable to it of the countries and jurisdictions in the Territory pertaining to the import, export, distribution, sales, and
marketing of Company Product. Without limiting the generality of the foregoing, each party will, as required by law of such party, (a) report to every applicable Regulatory Authority within any relevant time periods all events that are required
to be reported (including any death or serious bodily injury caused by a Company Product); and (b) deliver, within the permitted time periods, all annual or other periodic reports required to be delivered to every applicable Regulatory
Authority. 
 6.6 BioForm Inspection Rights; Regulatory Co-operation; Suppliers 
 (a) BioForm shall have the right to have its representatives present at the plant or plants at which Company Product is manufactured during normal
business hours to conduct an initial and periodic inspections of such facilities and manufacturing procedures for compliance with CGMP and QSR, the Product 

  

 – 13 – 

 
Specifications and BioForm’s quality assurance requirements and to inspect Supplier’s inventory of Company Product, work-in-process, raw materials
to be used for Company Product, production records, design history file, quality manuals, regulatory dossiers, and such other matters as may be pertinent to proper quality assurance of Company Product to be delivered hereunder. BioForm agrees to
give Supplier a minimum of five business days’ prior notice of any such inspection and each non-employee BioForm representative may be required by Supplier to sign a confidentiality agreement. Supplier shall promptly use its best efforts to
take such action as is required to correct any deficiencies identified by BioForm relating to the production of Company Product. Supplier further agrees to use its best efforts to provide such documentation or conduct such analyses as BioForm may
reasonably request in connection with any regulatory submission or audit. 
 (b) At BioForm’s reasonable request, Supplier will perform
a quality system assessment of the vendors who provide Supplier with raw components/materials, sub-assemblies or contract services for any Company Product. 
 6.7 Regulatory Audit. Supplier will permit authorized representatives of any Regulatory Authority to inspect Supplier’s plant and production facilities relating to or used in connection with the
manufacture of Company Product and will promptly notify BioForm when Supplier receives notice of any such inspection. Supplier will advise BioForm of the findings of any regulatory inspection and will promptly take the necessary steps to correct any
compliance deficiencies found by the Regulatory Authority relating to the production of Company Product. Supplier further agrees to use its reasonable best efforts to provide to BioForm such documentation or conduct such analyses as BioForm may
reasonably request in connection with any regulatory submission or audit concerning Company Product. BioForm will permit authorized representatives of any Regulatory Authority to inspect BioForm’s facilities relating to distribution of Company
Product and will promptly notify Supplier when BioForm receives notice of any such inspection. BioForm will advise Supplier of the findings of any regulatory inspection and will promptly take the necessary steps to correct any compliance
deficiencies found by the Regulatory Authority relating to BioForm’s activities with Company Product. 
 6.8 Complaints. BioForm
shall be responsible for all Company Product-related Complaint handling activities, evaluations, analyses, and regulatory communications. BioForm will enter all Complaints, as well as recommendations and analyses of Supplier, into BioForm’s
Complaint handling system. In connection with such Complaint activities: 
 (a) “Complaint” means any written,
electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released for distribution (marketed). 
 (b) “Complaint Evaluation” means a documented process for determining the root cause (or the most probable cause) of a Complaint.

 (c) At BioForm’s request, Supplier will cooperate and perform Complaint Evaluations for Complaints that may be the result of
Supplier’s actions (a “Process Complaint”) in order to determine any required corrective actions. Supplier will maintain records of such investigations as required by CGMP. Supplier has a period of seven calendar days
from the time it receives a Process Complaint from BioForm to perform a preliminary investigation that evaluates the root cause of the Complaint and makes a corrective action recommendation. Supplier will inform BioForm immediately of the results of
any such investigation and Supplier’s recommendations. BioForm will return to Supplier the Company Product unit that is the subject of the Complaint if such Company Product has been made available to BioForm. Supplier will also maintain a cross
reference system from Supplier’s complaint handling system to BioForm’s complaint handling system. Supplier will take reasonable actions to complete all corrective actions in connection with a Process Complaint within 90 calendar days.
BioForm acknowledges that some corrective actions may take 

  

 – 14 – 

 
more than 90 calendar days to complete. Upon BioForm’s request, Supplier will provide periodic updates until all corrective actions are complete.
Supplier will provide BioForm with a follow-up report on the effectiveness of the corrective actions within a reasonable time period. Without limiting the foregoing, to the extent required by applicable law, Supplier will report all Complaints to
the relevant Regulatory Authority in compliance with its obligations under Section 6.5. 
 (d) BioForm will promptly notify Supplier of
any corrective actions generated by BioForm relating to Company Product. Any such corrective actions that require action by Supplier will be specifically noted by BioForm and Supplier will provide a written response to BioForm within 15 calendar
days. BioForm may elect to increase this time period at its option. 
 6.9 Quality Plan. Supplier shall establish a quality plan which
will define the quality practices, the resources, and the activities relevant to Company Product and will periodically notify BioForm of any updates or revisions to the Quality Plan. This plan must be approved in writing by BioForm, which approval
will not be unreasonably withheld, conditioned or delayed. 
 6.10 Product Recalls 
 (a) If, in the judgment of Supplier or BioForm, any Company Product defect or any government action requires a recall of, or the issuance of an advisory
letter regarding, any Company Product, either party may undertake such recall or issue such advisory letter after consultation with the other party. Each party shall notify the other party in a timely manner prior to making any recall or issuing any
advisory letter. The parties shall endeavor to reach an agreement prior to making any recall or issuing any advisory letter regarding the manner, text, and timing of any publicity to be given such matters in time to comply with any applicable legal
or regulatory requirements, but such agreement will not be a precondition to any action that either party deems necessary to protect users of Company Product or to comply with any applicable governmental orders, regulations, or mandates. The parties
agree to provide reasonable assistance to one another in the event of any recall or issuance of any advisory letter. BioForm shall have the right to manage any recall within the Territory so long as such management does not prevent Supplier from
exercising its rights under this Section 6.10. 
 (b) In the event of a recall of Company Product, Supplier shall correct noted
deficiencies relating to its manufacture, packaging, testing, labeling, and Supplier’s storing or handling of Company Product (“Process Related Recalls”), if applicable, or cause the vendor of any material, component, or
sub-assembly incorporated into such Company Product to do likewise with respect to such material, component, or sub-assembly and BioForm shall correct noted deficiencies related to matters for which it is responsible. For Process Related Recalls,
Supplier shall, at BioForm’s option, either, at its cost replace each unit of the Company Product recalled (including units held in inventory by BioForm or its customers) with a corrected Company Product within a reasonable period of time, or
refund the purchase price therefor. Supplier shall promptly pay or reimburse BioForm for all costs and expenses (including shipping, quality control testing, notification, and restocking costs) incurred by BioForm as a result of any recall or
advisory letter (unless resulting from a deficiency caused by BioForm, in which case BioForm will reimburse Supplier for Supplier’s costs and expenses associated with such recall). 
 7. TRADEMARKS; IMPROVEMENTS; INTELLECTUAL PROPERTY 
 7.1 Trademarks. Except as may otherwise be
agreed to by the parties in accordance with Section 4.8, BioForm shall have no right to use the Supplier Trademarks in connection with the promotion, marketing, sale, distribution, and delivery of Company Product or otherwise and BioForm shall
not otherwise use the Supplier Trademarks in connection with the promotion, marketing, sale, distribution, or delivery of any Company Product except as may be required to comply with applicable law or regulations relating to 
  

 – 15 – 

 
distribution within the Territory of Company Product, and Supplier hereby grants to BioForm a license to do so. Except as may otherwise be agreed to by the
parties in accordance with Section 4.8, BioForm agrees not to use, distribute, or market any BioForm Trademarks in connection with any Company Product or otherwise that are sufficiently similar to any Supplier Trademarks as to create confusion
between Company Product and the BioGlue Surgical Adhesive. 
 7.2 Infringement 
 (a) Each of BioForm and Supplier will notify the other party in writing of any infringement of a Proprietary Right in the Field and in the Territory or
unauthorized disclosure or use of any Confidential Information pertaining to the Company Product within 15 calendar days after it becomes aware of such infringement or unauthorized disclosure. Supplier shall have the exclusive right to determine
what action, if any, to take in response to any such unauthorized use and to take all legal action it deems necessary or advisable to eliminate or minimize the consequences of any infringement of a Proprietary Right in the Field and in the
Territory. 
 (b) Supplier shall permit BioForm to participate at its own cost in any legal action brought by Supplier to eliminate or
minimize the consequences of any infringement of a Proprietary Right in the Field in the Territory; provided that Supplier shall maintain the right to control the prosecution of such action. 
 (c) If BioForm elects to participate in the legal action, all proceeds realized upon any judgment or settlement regarding an action undertaken pursuant
to Section 7.2(a) with respect to infringement of Proprietary Rights (net of direct out-of-pocket fees and expenses relating thereto) in the Field in the Territory shall be shared equally by Supplier and BioForm with respect to infringement of
Patent Rights. 
 (d) If BioForm can demonstrate that an infringing product has gained a minimum of [****] share of the market addressed by
the Company Product in the Field in the Territory taken as a whole, the Transfer Price paid by BioForm to Supplier for Company Product will decrease by [****] per unit. Such decrease will remain in effect until a Favorable Conclusion is obtained.
For the purposes of this Agreement, a “Favorable Conclusion” is defined as a cessation of the infringement, withdrawal of the infringing product from the Field in the Territory, reduction of the infringing products market
share in the Field in the Territory to less than [****], or other compromise conclusion to the infringement that is reasonably acceptable to both BioForm and Supplier. If a Favorable Conclusion cannot be obtained the decreased Transfer Price set
forth in this Section 7.2(d) will remain for the Term of this Agreement. 
 7.3 Patent Prosecution. Supplier shall apply for,
prosecute, and maintain the BSA Patents in the Territory. Supplier shall keep BioForm reasonably informed as to the status of the prosecution and maintenance of the BSA Patents in the Territory and with respect to any actions regarding the BSA
Patents in the Territory. Payment of all fees and costs relating to the filing, prosecution, and maintenance of the BSA Patents shall be the responsibility of Supplier. 
 8. CERTAIN OBLIGATIONS OF SUPPLIER 
 8.1 Product Information. Supplier will assist BioForm in
creating product handling manuals, sales literature, promotional materials, training materials, videos, demonstration kits, and other applicable information for Company Product by sharing with BioForm similar information developed and used by
Supplier with its BioGlue Surgical Adhesive. The material shared (collectively, the “Product Information”) shall include information Supplier has that it believes will he helpful and appropriate in assisting BioForm in
formulating any other manuals, promotional materials, and warning labels deemed necessary or appropriate by BioForm for Company Product. Product Information shared may be used by BioForm solely for the purpose identified above. 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 16 – 

 8.2 BioForm Materials. Portions of the Product Information may be incorporated into BioForm
materials used with Company Product but only in ways that avoid attribution to or association with Supplier or Supplier products other than Company Product. Supplier represents and warrants that the Product Information shall be accurate and complete
in all material respects, and undertakes to update any such Product Information when any information included therein becomes outdated, inaccurate, or misleading. BioForm acknowledges, however, that the Product Information relates specifically to
the BioGlue Surgical Adhesive and not the Company Product. BioForm shall have the right to produce, at its expense, promotional material, Company Product handling manuals, instructions for use, warning labels, and other written information relating
to Company Product that is based in whole or in part on the material supplied by Supplier subject to the limitations set forth above. BioForm reserves exclusive right and title in BioForm-created Company Product literature and documentation, subject
to Supplier’s retained rights in, and BioForm’s limited licensed rights to, any Product Information incorporated therein. 
 8.3
Training Advice and Assistance. Supplier will provide reasonable train-the-trainer technical assistance and training at Supplier’s facilities regarding Company Product for BioForm as BioForm reasonably requests. Supplier shall also
provide to BioForm other services or other support information to assist BioForm in marketing Company Product as BioForm reasonably requests. BioForm shall be responsible for all of its costs associated with obtaining the training and support
provided for under this Section 8.3. Supplier shall be responsible for the costs and expenses of its personnel incurred in connection with providing train-the-trainer technical assistance and training provided pursuant to this Section 8.3,
up to a maximum of [****] per year. 
 8.4 Product Development 
 (a) Supplier may develop enhancements it intends to incorporate into the BioGlue Surgical Adhesive during the term of this Agreement that have potential
application to the Company Product (“Enhancements”). Unless otherwise agreed by the parties, at least once every six months during the Term, representatives of each of BioForm and Supplier shall hold a meeting in
accordance with Sections 4.4 and 8.4 (the “Product Development Meeting”) at which Supplier will present Enhancements for BioForm to consider for application to the Company Product. At such Product Development Meeting, BioForm
will also present its marketing plans (pursuant to Section 4.4) for the period and any information or feedback that BioForm reasonably believes may lead to Improvements. Within 30 calendar days following each Product Development Meeting,
Supplier shall deliver a notice to BioForm (the “Enhancements Notice”) that shall describe the Enhancements that were presented by Supplier at such Product Development Meeting. Within 30 calendar days following receipt of the
Enhancements Notice, BioForm may notify Supplier in writing if BioForm elects that any Enhancement described in the Enhancements Notice shall become an Improvement. If BioForm does provide such notice to Supplier during such 30-calendar day period,
then BioForm and Supplier shall agree on a timeline for implementation of the Improvement in new Product Specifications for Company Product. If BioForm does not provide such a notice, said Enhancement shall not be implemented into the Company
Product. The Enhancements Notice may also describe any potential Enhancements presented by Supplier at the Product Development Meeting, but BioForm shall not be required to take any action under this Section 8.4 with respect to such potential
Enhancements until such time as they are presented by Supplier as Enhancements at a future Product Development Meeting. All Enhancements and potential Enhancement information provided by Supplier shall be considered Supplier Confidential
Information. 
 (b) From time to time, each party may request the other party to participate in joint projects to develop Improvements.
Neither party is obligated to participate in such projects, and in each 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 17 – 

 
instance, each party’s decision whether to participate will be made in such party’s sole discretion. If both parties mutually agree to participate
in such a project (a “Program”), the parties will promptly prepare a mutually agreeable written development agreement specifying the development activities to be performed by and the research and development tasks assigned to
each party (the “Development Agreement”). All allocation of Intellectual Property rights with respect to any Program will be set forth in writing in the Development Agreement. 
 (c) In the absence of a Development Agreement, (i) BioForm and Supplier shall retain joint ownership of Intellectual Property rights in which there
is joint inventorship by BioForm (or its Affiliates) and Supplier, as determined in accordance with United States patent law, with Supplier’s rights in such joint ownership being subject to the license rights of BioForm under this Agreement,
(ii) any Intellectual Property rights related to the Company Products, Enhancements, and Improvements that are created solely by employees or consultants of Supplier during the Term shall be considered to be Intellectual Property rights of
Supplier, subject to the license rights of BioForm under this Agreement, and (iii) any Intellectual Property rights related to the Company Products and Improvements that are created solely by employees or consultants of BioForm or any of its
Affiliates during the Term shall be considered to be Intellectual Property rights of BioForm. BioForm hereby grants to Supplier a perpetual, royalty free, world-wide, nonexclusive license to Supplier under such Blocking Intellectual Property to
make, use, and sell such Intellectual Property outside the Field. “Blocking Intellectual Property” for the purposes of Section 8.4(c)(iii) shall mean Intellectual Property necessary for Supplier to make, use, or sell SA
Product. 
 9. REPRESENTATIONS AND WARRANTIES 
 9.1 Mutual Representations and Warranties 
 (a) Supplier hereby represents and warrants that: 
 (i) it is a duly and validly organized and existing corporation in good standing under the laws of the state of Florida, and that it or its Affiliates
that may be performing its obligations under this Agreement are legally qualified to do business in each jurisdiction in which this Agreement may be performed and where its activities hereunder require such qualification, 
 (ii) the performance of this Agreement and the consummation of the transactions contemplated herein will not result in any breach, conflict, or
violation of any terms or provisions of, or constitute a default under, its Certificate of Incorporation or By-Laws, or other organizational documents, or any material agreement or instrument to which it is a party, by which it is bound, or to which
any of its property is subject, 
 (iii) all requisite corporate action has been taken for the due authorization, execution, delivery, and
performance of this Agreement by it, and this Agreement constitutes a legally binding obligation, enforceable against such party, in accordance with its terms, except insofar as enforceability may be limited by bankruptcy, insolvency,
reorganization, or similar laws affecting the rights of creditors generally, and 
 (iv) it is not a party to any litigation relating to, or
that could reasonably be expected to affect, its ability to perform its obligations under this Agreement. 
 (b) BioForm hereby represents
and warrants that: 
 (i) it is a duly and validly organized and existing corporation in good standing under the laws of the state of
Delaware, and that it or its Affiliates that may be performing its obligations under this Agreement are legally qualified to do business in each jurisdiction in which this Agreement may be performed and where its activities hereunder require such
qualification, 
  

 – 18 – 

 (ii) the performance of this Agreement and the consummation of the transactions contemplated herein will
not result in any breach or violation of any terms or provisions of, or constitute a default under, its Certificate of Incorporation or By-Laws, or other organizational documents, or any material agreement or instrument to which it is a party, by
which it is bound, or to which any of its property is subject, 
 (iii) all requisite corporate action has been taken for the due
authorization, execution, delivery, and performance of this Agreement by it, and this Agreement constitutes a legally binding obligation, enforceable against such party, in accordance with its terms, except insofar as enforceability may be limited
by bankruptcy, insolvency, reorganization, or similar laws affecting the rights of creditors generally, and 
 (iv) it is not a party to any
litigation relating to, or that could reasonably be expected to affect, its ability to perform its obligations under this Agreement. 
 9.2
Product Warranty. Supplier represents and warrants to BioForm that Company Product supplied to BioForm hereunder shall, during the applicable shelf life: (a) conform to the Product Specifications, (b) be manufactured, labeled,
packaged, and tested (while in the possession or control of Supplier) in accordance with applicable Product Approvals and applicable laws and regulations in each country or jurisdiction within the Territory for which Product Approval has been
obtained relating to the manufacture, labeling, packaging, and testing of Company Product, including those set forth in Section 6.1, (c) have a shelf life of at least two years when shipped to BioForm, and (d) be free and clear of
liens and encumbrances. 
 9.3 Non-Infringement. Supplier represents and warrants to BioForm that it knows of no Intellectual Property
rights of others that will be infringed by the development, manufacture, marketing, or sale of the Company Product by Supplier or BioForm as contemplated by this Agreement. 
 9.4 Title. Supplier represents and warrants to BioForm that Supplier has sufficient right, title, and interest in the BSA Patents and the
Proprietary Rights to perform its obligations under this Agreement and to grant BioForm the license and distribution rights that are granted in this Agreement. 
 10. INDEMNIFICATION AND LIABILITY 
 10.1 Infringement Indemnification 
 (a) Subject to the provisions of Section 10.3, Supplier shall defend, indemnify, and hold harmless BioForm, its subsidiaries, parent corporations,
Affiliates, officers, directors, independent contractors, partners, shareholders, employees, agents, and their respective successors and assigns from and against any claim, suit, demand, loss, damage, expense (including reasonable attorney’s
fees and those that may be asserted by a third party), or liability (collectively, “Losses”) arising from or related to an allegation that the development, manufacture, marketing, or sale of any Company Product in the
Territory infringes or misappropriates any Intellectual Property right of any third party, except for Losses that are the responsibility of BioForm pursuant to Section 10.1(b). If any Company Product is held to constitute an infringement or
misappropriation of any third party’s Intellectual Property right or if BioForm and Supplier concur that any Company Product constitutes an infringement or misappropriation, Supplier will at its expense either: (i) procure the right for
BioForm to continue distributing the Company Product in accordance with this Agreement at no additional cost to BioForm, (ii) replace the Company Product with a non-infringing and non-misappropriating equivalent product conforming to the
Product Specifications at no additional cost to BioForm, or (iii) modify the Company Product to make it non-infringing and non-misappropriating while conforming to the Product Specifications at no additional cost to BioForm. 
  

 – 19 – 

 (b) Subject to the provisions of Section 10.3, BioForm shall defend, indemnify, and hold harmless
Supplier, its subsidiaries, parent corporations, Affiliates, officers, directors, independent contractors, partners, shareholders, employees, agents, and their respective successors and assigns from and against any Losses arising from or related to
(i) an allegation that any BioForm Trademark used by BioForm in connection with the marketing or sale of Company Product infringes or misappropriates any trademark right of any third party, (ii) from any product description or claim made
by BioForm in writing or through electronic transmission that is not consistent with the product description and claims approved by Supplier, or (iii) a warranty claim asserted by any third party based on a warranty made in connection with
Company Product that was not approved in writing by Supplier. 
 10.2 Other Claims. Subject to the provisions of
Section 10.3, each of Supplier and BioForm (each, in such capacity, an “Indemnifying Party”) will defend, indemnify, and hold harmless the other party, its subsidiaries, parent corporations, Affiliates, officers,
directors, independent contractors, partners, shareholders, employees, agents, and their respective successors and assigns (collectively, in such capacity, the “Indemnitees”) from and against any Losses, including Losses
imposed upon or caused to be incurred by the Indemnitee(s) by any third party, arising from or related to (a) any material breach of such Indemnifying Party’s representations and warranties, covenants, or obligations under this Agreement;
or (b) any negligence or intentional misconduct by such Indemnifying Party (or its employees, agents, or representatives) in performing its obligations under this Agreement. The indemnification under the foregoing clause (b) shall not
apply in the event and to the extent that a court of competent jurisdiction determines that such Losses arose as a result of any Indemnitees’ negligence, intentional misconduct, or breach of this Agreement. 
 10.3 Procedure. A party seeking indemnification shall promptly notify the other party in writing of a claim or suit; provided, that a
party’s failure to give such notice or delay in giving such notice shall not affect such party’s right to indemnification under this Section 10 except to the extent that the other party has been prejudiced by such failure or delay.
Neither party has any obligation to indemnify the other party in connection with any settlement made without the Indemnifying Party’s written consent, which consent shall not be unreasonably withheld. The Indemnitee has the right to participate
(i) at its own expense in the claim or suit with counsel of its own choosing and (ii) in selecting counsel to be used by the Indemnifying Party in such claim or suit. The Indemnifying Party will consult with the Indemnitee in good faith
with respect to all non-privileged aspects of the defense strategy. The Indemnitee shall cooperate with the Indemnifying Party as reasonably requested, at the Indemnifying Party’s sole cost and expense. The Indemnifying Party shall not settle
any claim or suit without the Indemnitee’s prior written consent unless such settlement is limited to the payment of cash by the Indemnifying Party and contains a full release of the Indemnitee. 
 10.4 Insurance. At all times during which any Company Product is being clinically tested with human subjects or commercially distributed or sold
by BioForm hereunder, as well as for a period of seven years thereafter, Supplier shall procure and maintain from a reputable insurer reasonably satisfactory to BioForm insurance, including product liability insurance, adequate to cover its
obligations hereunder and which is consistent with normal business practices of prudent companies similarly situated. Such insurance policy shall at all times name BioForm as an additional insured thereunder and Supplier shall provide a certificate
of insurance to BioForm evidencing such coverage. It is understood that such insurance shall not be construed to create a limit of Supplier’s liability with respect to its indemnification obligations under this Section 10. Supplier shall
provide BioForm with written evidence of such insurance (or financial information that describes the amounts available under any self-insurance facility) upon request. Supplier shall provide BioForm with written notice at least 15 calendar days
prior to the cancellation, non-renewal, or material change in such insurance. 
  

 – 20 – 

 10.5 No Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, THE PARTIES MAKE NO
REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY REPRESENTATIONS OR WARRANTIES AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
 10.6 Limitation of Liability. SUPPLIER AND BIOFORM EACH AGREE THAT NO PARTY SHALL BE LIABLE TO ANY OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL,
EXEMPLARY, OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR NET PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE), OR OTHERWISE, EVEN
IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. 
 11. TERM AND TERMINATION 
 11.1 Term. This Agreement shall take effect as of the Effective Date and shall remain in effect until terminated in accordance herewith (the
“Term”). 
 11.2 Termination 
 (a) BioForm may terminate this Agreement upon [****] days written notice to Supplier if Supplier fails to meet its manufacturing and supply obligations under this Agreement for a period of [****]. 
 (b) Supplier may terminate this Agreement upon [****] days written notice to BioForm if (i) BioForm has not designed, funded, and conducted a
Regulatory Approval Plan and diligently pursued programs with the goal of obtaining FDA approval to market and sell a Company Product in at least one applicable indication within the Field, or (ii) BioForm fails to file with the FDA an IDE
submission in at least one applicable indication within the Field by [****] from the Effective Date, or (iii) enroll the first patient in a United States clinical trial within [****] from the date of IDE approval. 
 (c) Either party may terminate this Agreement at any time upon [****] calendar days written notice to the other party in the event that the other party
shall have materially breached any of its obligations, representations, or warranties hereunder and shall not have cured such breach prior to the expiration of such [****] period, which begins on the date that such written notice is received. Such
notice shall specify in reasonable detail the nature of the material breach. 
 (d) The parties may also terminate this Agreement at any time
upon mutual written agreement. 
 11.3 Exclusive Remedy. The parties agree that Supplier’s sole and exclusive remedy with respect
to a material breach by BioForm of any of the covenants set forth in Section 3.1 and Section 4.6 shall be to terminate this Agreement in accordance with Section 11.2(a), or, as applicable, 11.2(b) and receive the Development Effort
Data from BioForm if Supplier reimburses BioForm for all costs associated with the Regulatory Approval Plan, Regulatory Approvals and the physical transfer of the Development Effort Data. “Development Effort Data” means all
data obtained by BioForm in the process of implementing the Regulatory Approval Plan and obtaining regulatory authority to distribute Company Product. Supplier shall not bring, commence, continue, or prosecute any claim, legal action, or proceeding
under, in relation to, arising out of, or in connection with a breach of Section 3.1 or Section 4.6 except to cause the termination of this Agreement and obtain timely transfer of the Development Effort Data in accordance with this
Section 11.3. Notwithstanding and in addition to the rights conveyed by and limitations contained in this Section 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 21 – 

 11.3, Supplier may separately terminate its obligations under Sections 4.2, 4.3, and 4.9 at any time by so notifying
BioForm in writing if BioForm [****] of Company Product from Supplier in each 12 month period that commences at least 12 months after BioForm’s receipt of PMA approval or comparable Regulatory Approval from the FDA for at least one indication
within the Field, provided that, Supplier may only terminate its obligations pursuant to Sections 4.2, 4.3, and 4.9 after it has notified BioForm in writing of its breach and given BioForm 30 days to cure such breach. 
 11.4 Effect of Termination. Notwithstanding anything to the contrary contained herein, upon termination or expiration of this Agreement,
(a) Supplier shall continue to fill all BioForm Company Product orders made in accordance with the provisions of this Agreement prior to the date of such termination or expiration; (b) BioForm shall continue to have all rights necessary or
appropriate to sell Company Product (including Company Product delivered pursuant to post-termination orders and any Company Product ordered by BioForm prior to termination or expiration) for [****] following the date of termination or expiration,
and Supplier shall continue to comply with all of its duties and obligations hereunder necessary or appropriate to facilitate such sales by BioForm; (c) Supplier shall continue to comply with all of its duties and obligations hereunder
necessary or appropriate to permit BioForm to fulfill its obligations to deliver Company Product pursuant to tenders or sales contracts outstanding at the time of such termination or expiration until such tenders or sales contracts have expired,
including Supplier’s obligation to fill any related BioForm Company Product orders; and (d) BioForm shall take reasonable action to timely transfer to Supplier the Development Effort Data. Termination of this Agreement shall not affect
rights and obligations of either party that may have accrued prior to the effective date of termination or any obligation that by its nature or express terms survives termination. Without limiting the foregoing, the provisions of Sections 1, 5
(with respect to Company Product shipped prior to expiration or termination), 6.10, 8.4(c), 9 10, 11, and 12 shall survive any expiration or termination of this Agreement. 
 12. GENERAL PROVISIONS 
 12.1 Governing Law. This Agreement shall be governed by and construed
in accordance with the laws of the State of New York applicable to contracts executed in and to be performed in that jurisdiction, without giving effect to its rules regarding conflicts of laws. 
 12.2 Waiver. Except as otherwise expressly set forth herein, no provision of or right under this Agreement shall be deemed to have been
waived by any act or acquiescence on the part of either party, its agents, or employees, except by an instrument in writing signed by an authorized officer of each party. No waiver by either party of any breach of this Agreement by the other party
shall be effective as to any other breach, whether of the same term or condition or any other term or condition and whether occurring before or after the date of such waiver. 
 12.3 Independent Contractors. Each party represents that it is acting on its own behalf as an independent contractor and is not acting as an
agent for or on behalf of any third party. This Agreement and the relations hereby established by and between Supplier and BioForm do not constitute a partnership, joint venture, franchise, agency, or contract of employment. 
 12.4 Assignment. Neither party may assign its rights or obligations hereunder without the prior written consent of the other, which consent
may not be unreasonably withheld, conditioned or delayed; except that either party may assign its rights and obligations hereunder to a purchaser of all or substantially all of its assets or business without the other party’s consent. It is
understood that either party may, to the extent not expressly prohibited in this Agreement, from time to time perform some or all of its obligations hereunder through one or more of its Affiliates. It is further understood and agreed that either
party may grant a security interest in its rights under the Agreement to its lender. 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 22 – 

 12.5 Change of Control; Successors and Assigns. Notwithstanding any other provision of this
Agreement to the contrary, Supplier and BioForm will not consummate any sale, directly or indirectly, of all or substantially all of its assets or business relating to the Company Products (whether by stock sale, asset sale, merger, or otherwise)
unless the purchaser unconditionally agrees in writing, with a copy provided to the other party following closing of the transaction, that the terms of this Agreement shall be honored by the purchaser and that this Agreement shall be a binding
obligation of the purchaser. Supplier and BioForm agree to provide each other written notice of any transaction contemplated by this Section 12.5, under condition of confidentiality, including any change of control of Supplier or BioForm
(through a stock sale, asset sale, equity issuance, merger, or otherwise) prior to the closing of such transaction. This Agreement shall bind and inure to the benefit of the parties and their respective successors and permitted assigns. 

12.6 Publicity. Except as is necessary for governmental notification purposes or to comply with applicable laws and regulations or to
enforce their respective rights under this Agreement, and except as otherwise agreed to by the parties in writing, the parties shall (a) keep the material terms of this Agreement confidential and (b) agree upon the text and the exact
timing of any public announcement relating to the transactions contemplated by this Agreement. 
 12.7 Confidentiality. Each of
Supplier and BioForm acknowledge that in order to satisfy their respective obligations under this Agreement, it will be necessary for the parties to exchange certain Confidential Information. In consideration of the mutual benefits to be derived
from the exchange of Confidential Information, Supplier and BioForm agree as follows: 
 (a) Confidential Information of a disclosing party
shall be treated and safeguarded hereunder by the receiving party for a period of five years from the date of disclosure and with the same degree of care with which it treats its own Confidential Information of like character. Such receiving party
will not use Confidential Information for any purposes other than in connection with the relationship established by this Agreement. The receiving party warrants that it applies reasonable safeguards against the unauthorized disclosure and use of
Confidential Information. 
 (b) The receiving party agrees to limit access to the Confidential Information to such employees and consultants
of the receiving party who reasonably require such access in connection with the transactions contemplated by this Agreement. To the extent practicable, in the event that the receiving party is required to disclose any Confidential Information
pursuant to any law, regulation, or judicial or administrative directive, the receiving party shall promptly notify the disclosing party in order to allow the disclosing party a reasonable period of time to obtain protective or confidential
treatment of the Confidential Information before it is disclosed. 
 12.8 Further Assurances; Force Majeure. Each party covenants
and agrees that, subsequent to the execution and delivery of this Agreement and without any additional consideration, it will execute and deliver any further legal instruments and perform any acts that are or may become reasonably necessary to
effectuate the purposes of this Agreement. Any delay in the performance of any of the duties or obligations of either party shall not be considered a breach of this Agreement and the time required for performance shall be extended for a period equal
to the period of such delay; provided that such delay has been caused by or is the result of any act of God, embargo, strike, fire, flood, or other unforeseeable cause beyond the control and without the fault or negligence of the party so affected.
The party so affected shall give prompt notice to the other party of such cause, and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as possible. 
 12.9 Specific Performance. Each party acknowledges that it will be impossible to measure in money the damage to the other party if a party fails
to comply with the obligations imposed by Section 12.7 of this Agreement, and that, in the event of any such failure, the other party will not have an adequate remedy 

  

 – 23 – 

 
at law or in damages. Accordingly, each party agrees that injunctive relief or other equitable remedy, in addition to remedies at law or damages, is an
appropriate remedy for any such failure and will not oppose the granting of such relief on the basis that the other party has an adequate remedy at law. Each party agrees that it will not seek, and agrees to waive any requirement for, the securing
or posting of a bond in connection with any other party’s seeking or obtaining such equitable relief. 
 12.10
Notices. Unless otherwise provided herein, any notice, report, payment, or document to be given by one party to the other shall be in writing and shall be deemed given when actually received or when delivered personally or mailed by
certified or registered mail, postage prepaid (such mailed notice to be effective on the date that is three business days after the date of mailing), or sent by reputable overnight courier (such notice sent by courier to be effective one business
day after it is deposited with such courier), and in the case of BioForm, addressed to the attention of the Chief Financial Officer, at 1875 South Grant Street, Suite 110, San Mateo, California 94402, and in the case of Supplier, addressed to the
attention of Chief Operating Officer at 1655 Roberts Blvd. NW, Kennesaw, Georgia 30144, or to such other place as any party may designate as to itself by written notice to the other party. 
 12.11 Severability. In the event any provision of this Agreement shall for any reason be held to be invalid, illegal, or unenforceable in any
respect, such invalidity, illegality, or unenforceability shall not affect any other term or provision hereof. The parties agree that they will negotiate in good faith or will permit a court to replace any provision hereof so held invalid, illegal,
or unenforceable with a valid provision that is as similar as possible in substance to the invalid, illegal, or unenforceable provision. 
 12.12 Headings. Headings of the sections and subsections of this Agreement are for reference purposes only and shall not limit or affect the meaning or construction of the terms and conditions hereof. 
 12.13 Interpretation. Words such as “herein,” “hereinafter,” “hereof,” and “hereunder” refer to this
Agreement as a whole and not merely to a section or paragraph in which such words appear, unless the context otherwise requires. The singular shall include the plural, unless the context otherwise requires. Whenever the word “include,”
“includes,” or “including” appears in this Agreement, it shall be deemed in each instance to be followed by the words “without limitation.” 
 12.14 Entire Agreement; Amendment. The terms and provisions contained in this Agreement constitute the entire understanding of the parties with respect to the transactions and matters contemplated hereby
and supersede all previous communications, representations, agreements, and understandings relating to the subject matter hereof. No agreement or understanding amending, supplementing, or extending this Agreement shall be binding upon either party
unless it is in writing and signed by the applicable party. Without limiting the foregoing, the parties anticipate that the Exhibits, Annexes, and Schedules to this Agreement may be amended or supplemented from time to time by mutual written
agreement. 
 12.15 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. 
 [The remainder of this page is intentionally left blank.]

  

 – 24 – 

 IN WITNESS WHEREOF, the parties have caused this EXCLUSIVE DEVELOPMENT, DISTRIBUTION, AND
SUPPLY AGREEMENT to be executed by their respective duly authorized officers, and have duly delivered and executed this Agreement under seal as of the date first set forth above. 
  

							
	CRYOLIFE, INC.	    	BIOFORM MEDICAL, INC.
				
	By:	 	 /s/  D. Ashley Lee
	    	By:	 	 /s/  Steven L. Basta

	Name:	 	D. Ashley Lee	    	Name:	 	Steven L. Basta
	Title:	 	EVP, COO & CFO	    	Title:	 	President & CEO

 Exhibit A 
 BSA Patents 
  

							
	[****]	 	Country	 	Title	 	Status
	[****]	 	US	 	Adhesive Composition and Method	 	Issued
				
	[****]	 	Austria	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Belgium	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Canada	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Denmark	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Europe	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Finland	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	France	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Germany	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Greece	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
		 	Ireland	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending
				
	[****]	 	Italy	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
		 	Luxembourg	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending
				
		 	Monaco	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending
				
	[****]	 	Netherlands	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Norway	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
		 	Norway	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending
				
	[****]	 	Portugal	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
		 	Spain	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending
				
		 	Sweden	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending
				
	[****]	 	Switzerland &
Liechtenstein	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
		 	United
Kingdom	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 26 

 Exhibit B 
 BSA Specifications 
 BioGlue® Surgical Adhesive is a two-component surgical adhesive composed of purified bovine serum albumin and glutaraldehyde. The solutions are dispensed by a controlled delivery system, composed of a reusable delivery
device, applicator tips, and applicator tip extenders. Once dispensed, the adhesive solutions (in a pre-defined ratio) are mixed in the applicator tip where cross-linking begins. The glutaraldehyde molecules covalently bond (cross-link) the bovine
serum albumin molecules to each other and, upon application, to the tissue proteins at the repair site, creating a flexible mechanical seal independently of the body’s clotting mechanism. The delivery device-mediated application is designed to
provide reproducible mixing of the components in vitro. BioGlue begins to polymerize within 20 to 30 seconds and reaches its bonding strength within 2 minutes. BioGlue also adheres to synthetic graft materials via mechanical interlocks within
the interstices of the graft matrix. The BioGlue component has a shelf life of 3 years if stored at 25°C. 
  

			
	Test	 	 Specifications

		
	Container Integrity	 	Container is sealed with no evidence of damage
		
	Product Integrity	 	Product shows no sign of damage
		
	Seal Integrity of Inner and
Outer Pouches	 	All 4 seals complete and intact.
		
	Conformance of
non-irradiated product
code	 	Parent lot of non-irradiated material meets conformance requirements
		
	[****]	 	[****]
		
		 	[****]
		
	Count	 	Quantity of containers in batch shipped is equal to quantity irradiated and received
		
	Manufacturer and Part
Number	 	Meets that specified for pouched irradiated product code
		
	[****]	 	[****]*
		
	[****]	 	[****]*
		
	[****]	 	[****]
		
	[****]	 	[****]
		
	[****]	 	[****]
		
	Seal Strength of Outer Pouch
Seals	 	> 0.5 lbs/in.
		
	[****]	 	[****]
		
	[****]	 	[****]
		
	[****]	 	[****]

	*	The release criteria are the acceptance criteria for release of the product. The product specifications are parameters that must be met at the end of the product’s shelf-life.

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 27 

 Exhibit C 
 EC Countries 
 United Kingdom 
 France 
 Spain 
 Germany 
 Italy 
 Belgium 
 Luxembourg 
 The Netherlands 
 Switzerland 
 Austria 
 Ireland 
 Portugal 
  

 28 

 Exhibit D 
 Trademarks 
 BioGlue® and CryoLife BioGlue® 
  

 29 

 Exhibit 3.1(b) 
 Preliminary Regulatory Approval Plan 
 The contents of this exhibit are preliminary and subject to change based on i)
discussions with the FDA or applicable regulatory authorities; ii) in BioForm’s reasonable business judgment; and iii) in accordance with Section 3.1 and 3.2 of the agreement. 
 United States Regulatory Approval Plan 
 BioForm is preparing a regulatory strategy in the U.S. to secure PMA approval
to sell BioGlue for certain indications in the Field. The current strategy contemplates submitting an IDE to the U.S. FDA to conduct a pivotal clinical study in the U.S. Following execution of this agreement, BioForm plans to work closely with the
FDA to determine the appropriate endpoints and study parameters to secure such approval. Such discussions may impact the timing and study design as outlined below and BioForm will evaluate and modify, in its discretion, the regulatory approval
program accordingly. The details of the contemplated clinical study are listed below. 
 EU & Canada Regulatory Approval Plan 
 BioForm is currently evaluating regulatory strategies to secure approval for a CE Mark and the appropriate Canadian license to sell BioGlue for certain indications in the
Field. The current strategy contemplates [****] dossier in concert with CryoLife and the appropriate notified bodies [****] 
 BioForm believes that the
current data available [****], but are also determining [****]. Following the execution of the contract, BioForm will contact the respective regulatory authorities to determine the appropriate steps required to secure such approval. These steps may
include additional clinical evaluations in certain countries and depending on the outcome of such discussions, BioForm will make a determination as to the feasibility of such requests in the context of market size, opportunity and costs required to
enter these respective markets. BioForm also is contemplating certain multi-stage regulatory strategies to first secure labeling to enter the markets with the possibility of conducting additional clinical or post-market evaluations to potentially
expand the labeling. 
 BioForm will apply appropriate regulatory and financial resources utilizing both internal resources and outside consultants. BioForm
expects to work closely with CryoLife to provide references to clinical data and to facilitate conversations with the appropriate regulatory authorities. The contemplated budget has yet to be determined and will depend on the outcome of our
discussions with the regulatory authorities. 
 Potential U.S. Clinical Study Outline: 
 IDE PREPARATION OVERVIEW: 
 BioForm is planning to conduct a clinical
development program to seek at least one indication PMA approval from the FDA in the United States in the Field. BioForm believes that [****] the timelines in this plan will be adjusted accordingly. 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 30 

 The IDE will include such standard provisions as a report of prior investigations of BioGlue, investigational plan,
investigator information, manufacturing information, IRB information, informed consent, among others and some of which will incorporate by reference CryoLife’s existing clinical and regulatory information. The IDE submission is currently under
development 
 PROPOSED STUDY OBJECTIVE & DESIGN: 
 The proposed pivotal clinical study will be prospectively defined to evaluate the effectiveness and safety of BioGlue in browlift surgery. The study design is currently contemplated to entail one of the following protocols: 
  

	•	 	 [****] 

  

	•	 	 [****] 

  

	•	 	 [****]. 

  

	•	 	 Other designs or comparisons to be determined 

 ENDPOINTS: 
 Effectiveness measures may be determined by the vertical lift of the brow following the procedure at various time points. As
currently contemplated (in preliminary draft form)The patients may be seen post-operatively at [****] and at [****], [****], [****], [****], and [****] post surgery in order to evaluate the healing process as well as the brow elevation. It’s
expected that efficacy may be assessed out to [****] and safety will be evaluated through [****]. 
 The level of vertical lift or suspension that is
clinically relevant shall be determined and agreed to in concert with the FDA. BioForm currently contemplates the following assessment criteria: 
  

	 	•	 	 [****]. 

  

	 	•	 	 Patients will be evaluated closely for any potential side effects associated with the surgery and BioGlue. 

 PATIENT POPULATION: 
 BioForm expects to implement standard inclusion
and exclusion criteria to screen a population of evaluable patients for this study. 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 31 

 STATISTICAL CONSIDERATIONS: 
 Standard statistical methods will be employed to determine primary and secondary efficacy and safety outcomes. Depending on the final study design, BioForm may consult with appropriate statistical authorities to both determine the
effectiveness of the surgery and accurately assess a change over time using a 95% confidence interval. 
 NUMBER OF INVESTIGATOR SITES &
PATIENTS: 
 BioForm expects to enroll up to [****] patients at up to [****] investigator sites. Standard screening and evaluation criteria may be
employed to identify the appropriate patient population. 
 POTENTIAL TIMELINE & BUDGET: 
  

					
	 Task
	  	 Potential
Date
	 	 Cost

			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	
			
	 [****]
	  	[****]	 	
			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	[****]

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 32 

 Exhibit 4.3 
 Other Distributors 
 Supplier has distribution agreements for its BioGlue Surgical Adhesive with [****] covering
[****] the EC Countries and [****] in Canada. While these agreements do not grant rights to distribute Company Product in the Field, the contracts themselves do not explicitly prohibit the sale of BioGlue Surgical Adhesive in the Field. Approved
applications for BioGlue Surgical Adhesive in the EC Countries and Canada are as follows: BioGlue is indicated for use as an adjunct to standard methods of surgical repair (such as sutures, staples, electrocautery, and/or patches) to bond, seal
and/or reinforce soft tissue. BioGlue may also be applied alone to seal and/or reinforce damaged parenchyma when other ligature or conventional procedures are ineffective or impractical. Indicated soft tissues are cardiac, vascular, pulmonary,
genitourinary, dural, alimentary (esophageal, gastrointestinal, and colorectal), and other abdominal (pancreatic, splenic, hepatic, and biliary). Additionally, BioGlue is used in the fixation of surgical meshes in hernia repair. For general surgical
repair procedures, BioGlue may be used to aid in the sealing, bonding, and reinforcing of parenchymal tissues. 
 Countries covered by referenced
distribution agreements are [****] 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 33

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}]]